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Antidepressants 
Antidepressants for the treatment of depression have been on the market since the 1950s. 
Two specific classes were introduced: the monoamine-oxidase inhibitor iproniazide which 
is chemically related to isoniazide and which was first developed as a tuberculostatic drug 
but proved also to have antidepressant properties, and tricyclic antidepressants (TCAs) [1]. 
The pills were considered ‘miracle cures’ and revolutionized the treatment of depressive 
symptoms [1, 2]. However, it was not until the introduction of selective serotonin reuptake 
inhibitors (SSRIs) in the late 80’s that antidepressants became so immensely popular [1, 
3]. Older antidepressants caused serious adverse drug reactions and posed a potential 
risk for overdose, whereas SSRIs selectively target the neurotransmitter serotonin which 
is associated with fewer types of adverse drug reactions [4]. From then on, antidepressant 
drug use increased exponentially over the years [3, 5]. Recently, it was estimated that almost 
1 million persons in the Netherlands were prescribed an antidepressant in 2013 [6]. This 
is approximately 5.8% of the total Dutch population. Although some antidepressants may 
have been prescribed for other indications [e.g. pain], concerns have been raised regarding 
the high prevalence of antidepressant drug prescribing and its off-label use [7, 8]. It was 
proposed that antidepressants might be prescribed too easily for off-label indications or 
mild depressive symptoms, while effectiveness is not always proven and antidepressants 
are not free of risks [7-11]. 
Elderly population 
Especially in a specific population such as the elderly, antidepressants should potentially 
be prescribed with more care. Elderly are underrepresented in clinical trials, therefore it is 
difficult to predict the effectiveness and prevalence or severity of adverse drug reactions 
in the older population in daily practice [12, 13]. The trial population is younger, healthier 
and psychologically different [14]. Ageing conforms to physiological changes which alter 
pharmacokinetic mechanisms. This may increase the risk of drug toxicity and adverse drug 
reactions [13]. Besides, the context of treatment is different in the elderly population. They 
often have multiple comorbidities which require drug treatment [15], while on the other 
hand subsequent polypharmacy increases the risk of drug-drug interactions and adverse 
drug reactions [16]. Moreover, off-label indications, non-adherence or early discontinuation 
of treatment are common in daily practice and should also be taken into account [9, 17, 18]. 
Thus, studies in real-life settings are needed to investigate the safety of antidepressants in 
the specific population of elderly. 
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Rotterdam Study and Integrated Primary Care Information project
Studies in this thesis were embedded in the prospective population-based Rotterdam Study 
cohort, or data were retrieved from the Integrated Primary Care Information (IPCI) project, 
respectively. First, the Rotterdam Study is situated in Ommoord, a suburb of Rotterdam, and 
consists of 14,926 participants all aged 45 years or older [19, 20]. Follow-up examinations 
are conducted every 4-5 years. Medication dispensing data is available on a daily basis, and 
major morbidity and mortality are continuously monitored since 1990 onwards. Second, the 
IPCI project is an observational dynamic database which contains electronic medical records 
from general practitioners [21, 22], comprising approximately 1.5 million individuals in the 
Netherlands. These records are de-identified and contain data on diagnoses, laboratory 
findings, hospitalizations, discharge letters, and drug prescriptions. 
Aim and outline of the thesis
In this thesis, we had two main aims: 1) to study the characteristics of antidepressant use 
in clinical practice 2) to study the unintended effects of antidepressant treatment in clinical 
practice in an ageing population. 
In chapter 2, we aimed to characterize antidepressant use in the general older Dutch 
population in clinical practice. In chapter 2.1 and 2.2, we reported the prevalence and 
incidence of antidepressant use over a 15- and 20-year period in the Netherlands and in 
the Rotterdam area, respectively. Besides, indications for treatment and persistence to 
treatment are also briefly discussed, but are covered in more detail in consecutive chapters. 
In chapter 2.3, we assessed all possible indications for antidepressant treatment based on 
self-report, while we studied persistence and adherence to antidepressant treatment in 
chapter 2.4. 
In chapter 3, we aimed to assess potential unintended effects related to antidepressant 
treatment. In previous studies, antidepressants with a high potential to inhibit serotonin 
reuptake (mostly SSRIs) were associated with an increased risk of clinical bleedings [23, 24]. 
Antidepressants have never been studied in association with subclinical microbleeds, which 
are highly prevalent in the general population and have been linked to larger intracerebral 
hemorrhages [25, 26]. In chapter 3.1 and 3.2, we studied the association between use 
of antidepressants, categorized by their affinity for the serotonin transporter, and the 
presence of, or incident occurrence of, cerebral microbleeds defined on MRI. Moreover, in 
chapter 3.3, we studied the association between use of SSRIs and sleep quality assessed 
with a questionnaire. SSRIs have a positive effect on subjective sleep in clinically-depressed 
populations; however, the possible relief in depressive symptoms is an important and time-
varying confounding factor. Studies in healthy individuals are inconsistent and evidence 
for an association between SSRIs and better sleep in daily practice is lacking [27-30]. 
Furthermore, a well-known adverse drug reaction is SSRI-induced hyponatremia, with an 
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occurrence ranging between 0.06 and 40% [31]. However, the underlying mechanism of 
antidepressant-induced hyponatremia is still under debate, and the less extensively studied 
TCAs or other antidepressants also seem to be associated with hyponatremia but to a lesser 
extent [31, 32]. Therefore, in chapter 3.4, we assessed the association between use of all 
antidepressants and the occurrence of hyponatremia based on electronic medical records 
from general practitioners. Finally, in chapter 3.5, we focused on the association between 
use of SSRIs and change in bone mineral density. SSRIs are assumed to play a role in bone 
metabolism via the modulation of serotonin levels [33]. However, so far, longitudinal studies 
showed conflicting results and had limited longitudinal exposure information [34-36]. 
The contributions of all authors to the chapters within this thesis are specified in Table 
1. To conclude, we discuss the most important results of the studies presented in this 
thesis in chapter 4. Furthermore, we will discuss methodological considerations and future 
perspectives for upcoming research. A summary of the main results can be found in chapter 
5. 
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Utilization patterns of antidepressants between 1991 and 2011 
in a population-based cohort of middle-aged and elderly
Nikkie Aarts, Raymond Noordam, Albert Hofman, 
Henning Tiemeier, Bruno H. Stricker, Loes E. Visser
Eur Psychiatry. 2014 Aug;29(6):365-70
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Abstract
Background: In middle-aged and older patients in whom antidepressant use increased 
in last decades, patterns of use might be of concern. The objective of this study was to 
investigate the patterns of prevalence, incidence and duration of antidepressant use in an 
ageing population. 
Methods: All participants (aged ≥ 45 years) from the population-based Rotterdam Study 
were followed from January 1st 1991 until death, loss to follow-up, or end of the study 
period (December 31st 2011). Antidepressant drug dispensing, based on pharmacy records, 
were subdivided into tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors 
(SSRIs) and other antidepressants. One-year prevalence, 5-year incidence and duration of 
antidepressant use were calculated. 
Results: Yearly prevalence of antidepressant use increased from 3.9% in 1991 to 8.3% 
of the population in 2011. The increase in SSRI use was 5.8-fold, whereas use of other 
antidepressants doubled and TCA use remained stable over time. Incidence of all 
antidepressants decreased from 19.2 to 15.1 per 1,000 person-years between 1992 and 
2011. The duration of a first treatment episode increased over time. 
Conclusion: Despite the increase in prevalence of antidepressant use over time, incidence 
did not, which is most likely explained by a longer treatment duration and recurrent episodes. 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Utilization patterns between 1991 and 2011  |  19
2.1
Introduction 
During the last decades, the number of antidepressant drug prescriptions has increased in 
the Western countries [1-6], especially in elderly populations [4-7]. Given these rising trends, 
concerns are raised on the justification of antidepressant drug use [8-11]. Antidepressant 
drugs are not risk free, especially the elderly have an increased risk of drug-drug interactions 
and adverse drug reactions [12, 13]. Regularly, it is suggested that the rise of antidepressant 
drug use may indicate that the threshold to prescribe antidepressants has been lowered. 
Also, antidepressant drug prescriptions are prescribed to a broader range of patients 
without psychiatric diagnosis [3, 5, 14, 15]. Especially, an excessive rise in the total number 
of selective serotonin reuptake inhibitor (SSRI) prescriptions was observed [4-6]. Compared 
to tricyclic antidepressants (TCAs), SSRIs might be prescribed more easily and are taken for 
longer periods, since they have a milder adverse effect profile, a lower risk of toxicity and 
do not require monitoring of plasma levels [4, 6]. In contrast to the increasing number of 
prescriptions, recent studies of adult populations in Western countries showed a declining 
or constant rate of incident antidepressant users over the years after 2000. These trends 
were observed for all age categories [4, 5, 16]. However, before the year 2000, incident use 
of SSRIs still increased in the Netherlands [2]. Similar to other Western countries, dispensing 
trends and the number of antidepressant users also showed a steep increase during the last 
decades in the Netherlands [6, 17, 18]. Immediately after the introduction of SSRIs on the 
market in the 1980s, SSRIs were increasingly prescribed. Especially in the elderly, SSRIs are 
more desirable as first choice of treatment, considering the anticholinergic characteristics 
of TCAs [12, 19]. 
Recent utilization studies, which combine multiple utilization characteristics, are missing 
in the middle-aged and elderly. To understand the rising trends of antidepressant drug 
use, more utilization characteristics are needed besides dispensing trends. Therefore, 
the objective of our study was to investigate antidepressant drug utilization (incidence, 
prevalence and duration of antidepressant drug use) within a population-based cohort of 
middle-aged and elderly over a 21-year period from 1991 through 2011.
Methods 
Setting 
The Rotterdam Study is a prospective population-based cohort in which incidence and 
risk factors of diseases in an ageing population are investigated. From 1990 to 1993, all 
inhabitants aged 55 years or over in the Ommoord district in the city of Rotterdam in 
the Netherlands, were invited to participate in the Rotterdam Study I. The response rate 
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was 78%, including a total of 7,983 participants. Moreover, in 2000 and 2006 extended 
cohorts were enrolled. All inhabitants of Ommoord, aged 45 years of age and older and not 
already previously enrolled were invited to participate. A total of 6,943 participants were 
additionally included (response rate 66%). Informed consent was signed by all participants; 
including permission for retrieval of medical records and use of pharmacy data. The medical 
ethics committee of the Erasmus Medical Center, Rotterdam, the Netherlands, approved 
the study. After baseline measurements, follow-up examinations were conducted every 
4–5 years including interviews and an extensive set of examinations. Furthermore, fully 
computerized pharmacy records from the pharmacies in the Ommoord district continuously 
monitored pharmacy records from January 1st 1991 onwards. All information is available in 
a computerized format on a day-to-day basis. This includes the date of dispensing, the total 
number of drug units per dispensing, the dispensed daily number of units, the product name 
of the drugs and the Anatomical Therapeutic Chemical code (ATC). Detailed information on 
design, objectives and methods of the Rotterdam Study has been described elsewhere [20, 
21].
Study population 
For our study population, we included participants who were in the Rotterdam study 
after January 1st 1991, as fully automated pharmacy data was available since that date. 
All participants were followed until death, loss to follow-up or end of the study period 
(December 31st, 2011). Participants who were followed in a calendar year contributed to the 
denominator of the prevalence analyses. For the incidence analysis, follow-up started 1 year 
after entering our study to ensure that participants were incident users. Follow-up was until 
death, loss to follow-up, end of study period, or incident antidepressant use. Antidepressant 
drug users in the first year and prevalent users were censored and did not contribute to the 
person-years for the incidence analysis. Participants could only become an incident user 
once. After their first dispensing, they were censored for incidence analysis. Denominators 
of the incidence calculations were person-years of participants who were included in 
the follow-up, and were not excluded based on the previous requirements. However, in 
additional analyses, participants could also become recurrent incident antidepressant drug 
users and were then still at risk after incident antidepressant drug use.
Outcome definitions 
Dispensings with ATC-codes N06AA (TCA), N06AB (SSRI) or N06AF/N06AG/N06AX (other) 
were defined as antidepressant drug dispensing. The dispensing lengths were calculated in 
days by dividing the number of units issued per prescription by the dispensed daily number 
of units. Corresponding daily doses were expressed as the daily numbers of standardized 
defined daily doses (DDD). To describe the dispensing patterns of antidepressant drugs we 
calculated the prevalence, incidence rate and duration of use over the calendar years. 
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Prevalence of antidepressant drug use was defined as the number of antidepressant 
users with at least one dispensing in one year per total number of participants present in 
that year. In case of switching between antidepressant drug classes within one calendar year, 
a participant was counted only once for the overall prevalence, whereas the antidepressant 
drug user could contribute to other antidepressants drug classes within a year. Moreover, 
we also defined the prevalence of more adequate antidepressant drug use, to exclude 
single-filling antidepressant drug users. We took as cut-off at least four antidepressant drug 
prescriptions within a year interval. 
The incidence rate indicates the number of incident users within a 5-year interval 
divided by the total person-years at risk during those 5 years. Moreover, the duration of 
use of the first episode was calculated for the incident users who had a follow-up of at 
least two years at start of treatment. Duration was defined as the number of days from 
the date of the first antidepressant drug prescription until end of the drug episode. A gap 
of 90 days was allowed between the dispensings. When this gap of 90 days was exceeded, 
discontinuation of treatment was assumed. Moreover, we determined whether participants 
started antidepressant drug treatment again after at least 90 days after discontinuation of 
antidepressant therapy. If they initiated treatment again after 90 days, these participants 
were considered recurrent users and this would represent re-initiation of treatment [22]. 
Incidence rates for these recurrent users were the number of (recurrent) incident users 
within a 5-year interval divided by the total person-years at risk during those 5 years.
Co-factors 
Age and sex were studied as potential determinants of prevalent and incident use of the 
different antidepressant drug classes. Age was used as categorical variable. Age categories 
were based on the ranking of age for the different calendar years, with similar group sizes. 
They were categorized into four age groups: 45–64, 65–71, 72–77, and > 78 years of age. 
Data analysis
Incident rates over the calendar years (1992–2011) were studied for specific trends when 
split by age categories, sex, and type of antidepressant (TCA/SSRI/other). Incidence rates 
were shown in categories of 5 years. Similar trends were studied for the prevalence of 
(adequate) antidepressant drug use from 1991 until 2011. Moreover, incidence rates with 
recurrent users were calculated and incidence proportions were calculated for the different 
antidepressant drug classes. Proportions were calculated as percentage of the total number 
of incident users per 5 years. Finally, cox proportional hazard regression models were used 
to study calendar year (1992–2011) and type of antidepressant as potential determinants 
of discontinuation of treatment. Discontinuation of treatment was the outcome of interest 
and indicated (preliminary) discontinuation of treatment.
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Results
Study population characteristics
The total study population of the Rotterdam Study comprised 14,926 participants with an 
average age of 65.5 years (SD 10.5) at baseline of whom 59.1% were female (Table 1). In 
total, 89,622 antidepressant drug prescriptions were dispensed by the pharmacies during 
follow-up. A total of 1,905 incident users were observed during the 113,308 years of follow-
up. The average starting dose was 0.79 DDDs (SD 0.31) for SSRIs, 0.31 DDDs (SD 0.22) for 
TCAs and 0.64 DDDs (SD 0.66) for other antidepressants. 
Table 1. Characteristics of the study population. 
Study population
(N= 14,926)
Age (years)
    Mean (SD) 65.5 (10.5)
Sex (% female) 8,823 (59.1)
Total number of antidepressant drug prescriptionsa 89,622
Total follow-up (years) 113,308
Follow-up (years)b
    Mean (SD)
Number of incident usersb
9.6 (6.0)
1,905
Start dose incident users (PDD/DDD ratio)
    Mean (SD)
      TCA 
      SSRI
      Other
0.31 (0.22)
0.79 (0.31)
0.64 (0.66)
a Total of number of antidepressant drug prescriptions after 01-01-1991. b After 01-01-1992, after the exclusion criteria. 
Abbreviations: SD= standard deviation, PDD = prescribed daily dose, DDD = defined daily dose, TCA = tricyclic antidepressant, 
SSRI = selective serotonin reuptake inhibitor.
Prevalence 
There was a 2.1-fold increase in the annual prevalence of overall antidepressant use from 
3.9% in 1991 to 8.3% in 2011. This increase was also observed if analyses were performed 
stratified by sex (women 2.1-fold, men 2.3-fold). Women had on average a higher 1-year 
prevalence of antidepressant drug use over the calendar years than men, 7.9% (SD 2.0) versus 
4.3% (SD 1.0), respectively. The prevalence of ‘adequate antidepressant drug treatment’ 
showed a steeper increase (2.4-fold), from 2.1% in 1991 to 5.1% in 2011. Figure 1 illustrates 
the 1-year prevalence over the calendar years stratified by the type of antidepressant. The 
largest increase was seen for SSRI use, with a 5.8-fold increase between 1991 and 2011. The 
same, but less pronounced, increase was observed for the other antidepressants (2.1-fold); 
while prevalent use of TCAs remained relatively stable. Amitriptyline (24.6%) and paroxetine 
(25.9%) are the most commonly dispensed antidepressants. The other antidepressants with 
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mirtazapine (6.2%) and venlafaxine (5%) of all dispensings were also commonly prescribed. 
The higher age categories showed on average a higher prevalence of antidepressant use. 
This was shown in the age categories of 72–77 years of age (6.5%, SD 0.8) and in elderly > 78 
years of age (7.4% , SD 1.7) when compared with the two lower age categories 45–64 year 
(6.3%, SD 2.3) and 65– 71 years (6.0%, SD 1.3). All age categories showed an increase in the 
annual prevalence. 
Figure 1. Annual prevalence of the different antidepressant drug classes over the calendar years.
Abbreviations: TCA= tricyclic antidepressant, SSRI= selective serotonin reuptake inhibitor. 
Incidence 
A total of 1,905 individuals received a first dispensing of an antidepressant drug between 
1992 and 2011. Overall, total incidence of antidepressant drug use decreased from 19.2 to 
15.1 per 1,000 person-years (PY) between 1992 and 2011. Incidence rates were on average 
higher in women (19.4 incident users per 1,000 PY, SD 2.7) than in men (13.8 incident users 
per 1,000 PY, SD 3.0). The higher age categories (72–78 years, > 78 years) had on average 
a higher annual incidence rate over the 20-year period, respectively 17.5 (SD 4.3) and 22.1 
(SD 6.2) incident users per 1,000 PY versus 14.6 (SD 2.5) and 13.7 (SD 4.2) incident users 
per 1,000 PY in the lower age categories. Of the 1,905 incident users and their recurrent 
episodes, we showed an increased incidence rate over the calendar years, from 30.7 to 33.8 
per 1,000 PY between 1992 and 2011. Per 1,000 PY, incident use of SSRIs increased from 
5.9 in 1992–1996 to 9.5 individuals in 1997–2001 (Figure 2). After 2001, the incident rates 
decreased again, to an annual incidence rate of 5.3 antidepressant users in 2007–2011. 
Incident use of TCAS decreased over the 20-year time-interval (11.9 incident users per 1,000 
PY in 1992–1996 to 6.2 incident users per 1,000 PY in 2007–2011). Incident use of other 
antidepressants showed an increase from 1997–2001 onwards, from 0.6 incident users per 
1000 PY to 3.6 incident users per 1,000 PY in 2007–2011. 
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Figure 2. Incidence rates of antidepressant drug classes over the calendar years (5-year range). 
Abbreviations: TCA= tricyclic antidepressant, SSRI= selective serotonin reuptake inhibitor, PY= person-years. 
These trends were also reflected in the incidence proportions for the different 
antidepressant drug groups (Figure 3). The first choice treatment for SSRIs increased from 
30.7% until 55.7% of all incident antidepressant dispensings (1992–1996 until 1997–2001). 
After 2001, other antidepressants gained in popularity as initial dispensed antidepressant 
(3.3% until 23.7%). Overall, TCA use as a percentage of total incident antidepressant use 
decreased over the 20-year interval (62.0% until 41.0%). The percentages of incident 
antidepressant use show that amitriptyline (36.6%), paroxetine (19.7%) and mirtazapine 
(7.2%) are most often chosen at start of therapy. 
Figure 3. Proportions of antidepressant drug classes in incident users over the calendar years.
Abbreviations: TCA= tricyclic antidepressant, SSRI= selective serotonin reuptake inhibitor. 
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After adjustment for age and sex, the risk of discontinuation decreased over the calendar 
years in SSRI and other antidepressant drug users, showing longer treatment duration in 
later years than in the first calendar years of follow-up (Table 2). When considering the 
different antidepressant drugs as determinants for discontinuation, SSRI use (hazard ratio 
[HR] 0.68, 95%CI 0.61; 0.77) and other use (HR 0.70, 95%CI 0.59; 0.83) were associated with 
a longer treatment duration compared to TCA use. Modifying the minimal follow-up time 
for the duration analyses from two years to three or four years did not materially change 
the results. 
Table 2. The association between calendar years and risk of discontinuation. 
TCA
Hazard ratio
(95%CI)
SSRI
Hazard ratio
(95%CI)
Other
Hazard ratio
(95%CI)
Calendar years
   1992 - 1996  Reference Reference Reference
   1997 – 2001 1.06 (0.86; 1.31) 0.82 (0.66; 1.01) 1.23 (0.58; 2.60)
   2002 – 2006 1.03 (0.83; 1.27) 0.73 (0.58; 0.91) 0.69 (0.43; 1.11)
   2007 – 2011 1.09 (0.86; 1.39) 0.72 (0.55; 0.95) 0.65 (0.40; 1.06)
Calendar years were adjusted for age and sex. N= 1,432 incident users in the analyses, exclusion of incident users with a 
shorter follow-up than 2 years after start of treatment episode.  
Abbreviations: CI= confidence interval, TCA= tricyclic antidepressant, SSRI= selective serotonin reuptake inhibitor.
Discussion 
In this population-based cohort study of middle-aged and elderly in the Netherlands, we 
showed that the prevalence of antidepressant drugs increased from 1991 until 2011, while 
the number of incident users did not increase over the years. The increasing numbers of 
prevalent use are mostly related to the recurrent episodes of use. The duration of treatment 
also increased over the years, and was mainly caused by SSRI and other use, which were 
used more persistently. From 2000 onwards, SSRI incident use decreased, while incident use 
increased for other antidepressants. 
The 1994 guidelines from the Dutch College of General Practitioners suggested 
pharmacological treatment only for a severe depression, with TCAs being the first choice 
of pharmacological treatment [23]. The revision of these guidelines in 2003 did not make 
a distinction between mild and severe depression anymore, but the guidelines were more 
reserved regarding pharmacological treatment as first choice of treatment for depression 
[24]. SSRIs were considered equally beneficial to TCAs, and the choice of treatment should 
be based on the contraindications, possible adverse effects and previous treatment success. 
The original guidelines and the revision recommend 6 months of treatment continuation after 
disappearance of depressive symptoms [24, 25]. Since the changes in these guidelines are 
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minor, they cannot explain the decreasing numbers of incident users, the rising prevalence 
trends over the years and the excessive rise in use of SSRI and other antidepressants. 
We have no clear explanation for the decrease in incidence over the years. However, the 
observed decline in incident users might represent a saturation effect. Subjects who would 
start using antidepressants had already initiated an antidepressant drug, which will create 
a declining incidence. 
The opposing patterns observed between prevalent and incident use are in line with 
previous Western literature and were previously explained by the long-term treatment 
of antidepressant drugs [3-5]. An increase in treatment duration over the years has been 
reported [2], indicating that there is a better compliance with the (international) treatment 
guidelines to treat a depressive episode for at least 6 months after disappearance of the 
symptoms [23, 24, 26]. We also observed an increase in the duration of antidepressant drug 
treatment over the calendar years, and a steeper increase in prevalence of ‘‘more adequate 
antidepressant drug treatment’’. The increase in duration was mainly caused by SSRI and 
other use, which were used more persistently. Moreover, for the incidence analyses we 
only included the first episode of use, while after inclusion of recurrent antidepressant 
drug episodes we even observed a small increase in the incidence rates. The increase in 
duration of treatment and recurrent episodes might explain the opposing patterns between 
prevalence and incidence trends observed in our study. 
This study confirms the increase in SSRI dispensings in the middle-aged and elderly 
population [4, 6, 7]. A mild adverse drug reaction profile, low toxicity and no need for 
plasma monitoring for SSRIs might explain this [4, 6, 27]. Despite the excessive increase 
in SSRI dispensings, incident use of SSRIs decreased after 2000, which was already shown 
by a previous study and might be explained by the substitution with other antidepressants 
[5]. We showed an increased prevalence and incidence of other/newer antidepressants 
from 2000 until 2011, of which mirtazapine and venlafaxine were the most popular ones. 
Recent utilization figures of antidepressant use in the Western population also observed an 
increase in use of other antidepressants [4, 5, 18, 27]. The multidisciplinary guideline for the 
treatment of depression for medical specialists (and general practitioners) also mentioned 
mirtazapine as first choice of treatment because of beneficial characteristics [25]. The stable 
prevalence and small decrease in incident TCA use is consistent with previous literature [5, 
19]. We expected a larger decrease in TCA use, as they are not the first choice in the elderly 
population and other, more tolerable, antidepressants became available [4, 27, 28]. Specific 
guidelines were developed in later years for antidepressant drug use for the treatment 
of depression in the elderly, with SSRIs or nortrityline as first choice treatment [29]. The 
relatively high use of TCAs in our study might also be explained by the multiple indications 
for which antidepressant drugs are prescribed. For example, amitriptyline is often the choice 
of treatment for neuropathic pain, which is more common in the older adults and elderly 
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[28, 30]. The increase of antidepressant drug use with age was consistent with previous 
literature [4-7, 31]. This age-related effect may be related to worsening of chronic diseases, 
physical health problems and related disabilities or increasing loneliness [4, 5, 7, 32]. 
We should consider a number of issues when we evaluate the results. Indications of 
antidepressant drug use may vary over the years and are related to multiple person specific 
characteristics (e.g. age, sex and comorbidities). As the information regarding the indication 
of antidepressant drug use and the clinical condition of the subjects is missing, we could not 
draw conclusions regarding treatment appropriateness for different indications. Moreover, 
the study might be influenced by its finite population, as participants who are prone to 
start taking antidepressants become incident users, finally leaving the participants who 
are not susceptible to antidepressant drug use in the cohort. Moreover, participants in our 
study had to have a 1-year antidepressant drug free period at start of the study to become 
incident user which may have caused some misclassification [33]. However, because the 
findings in our study are in line with previous research about the prevalence and incidence of 
antidepressant use, we do not think the effect we observed is completely explained by these 
limitations. Participants of the Rotterdam Study lived in a district of the city of Rotterdam 
in the Netherlands, which might influence the generalizability of our study. Preferences for 
antidepressant drugs can differ per region [34], although antidepressant use in our study 
was not extraordinary compared to national trends [34, 35]. 
Our study has some strong points which we would like to emphasize. Firstly, since local 
pharmacies provided us with an electronically standardized list of all dispensed medications 
from nearly all participants of the Rotterdam Study and because these data were 
prospectively gathered without knowledge of our research hypothesis, information bias and 
recall bias were unlikely. Pharmacy data was only missing for hospitalized participants and 
participants who moved into a nursing home. This might have decreased our number of 
total antidepressant users, but we do not expect that specific trends are influenced by these 
missing data. Secondly, we presented an antidepressant drug utilization study with data up 
to 2012 and a total follow-up of 21 years (1991–2011). We did not only look at dispensing 
trends, but used incidence and duration of treatment as well to characterize antidepressant 
drug use. Thirdly, we focused our analysis only on the middle-aged and elderly population. 
Antidepressant drug use increases most in the elderly population, but they are also at a 
higher risk of drug-drug interactions and adverse events [4-7, 12].
Conclusion 
In our population of middle-aged and elderly, we can confirm the rise in antidepressant 
drug use. However, the total number of incident users did not increase. The rise might be 
explained by an increased duration of treatment and recurrent episodes of antidepressant 
drug treatment. Moreover, use of TCAs remained high in our middle-aged and elderly 
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population and we showed a shift from SSRIs to the other/newer antidepressants. With our 
results we gained more insight into antidepressant drug utilization patterns, which can be 
used to tackle the problems with high psychotropic drug use rates in the elderly.
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Abstract
Purpose: Antidepressant drug use increases worldwide. It is pivotal to closely monitor the 
use of antidepressants and to determine in what subpopulations the rise is most substantial. 
In a Dutch primary care database, we aimed to investigate the (sex- and age-specific) 
prevalence and incidence of antidepressant prescribing and to monitor the indication of 
incident prescriptions over a 17-year period (1996 – 2012). 
Methods: This study, embedded in the Integrated Primary Care Information database, 
included all patients aged 10 years or older. Per calendar year, prevalence and incidence 
of antidepressant drug prescribing were calculated by drug class (tricyclic antidepressants, 
selective serotonin reuptake inhibitors [SSRIs] and others), sex and age. The indication of 
incident prescriptions (e.g. depression, anxiety, sleep disorders and neuropathic pain) was 
determined based on the International Classification of Primary Care codes.
Results: In total, 1.49 million patients were included. For all antidepressants together, the 
prevalence increased over time. However, incident prescribing of specifically SSRIs decreased 
from 2000 onwards. During the study period, incidence and prevalence were higher in older 
and female patients. The increase in prevalence and the decrease in incidence were more 
pronounced in females than in males. Furthermore, antidepressants were increasingly 
prescribed for indications as neuropathic pain and sleep disorders instead of depression. 
Conclusions: In Dutch primary care, prevalent prescribing of antidepressants continued to 
increase, but incident prescribing of particularly SSRIs decreased from 2000 onwards. In later 
years, antidepressants were less frequently prescribed for depression-related indications in 
incident users. 
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Introduction
Antidepressant drug use increased substantially during the last decades [1-5]. The rise in 
antidepressants can be explained by an increasing number of indications (e.g. neuropathic 
pain and sleep disorders) and by a lower threshold to prescribe antidepressants [3, 4, 6, 
7]. The rise in use was shown to be most pronounced for the selective serotonin reuptake 
inhibitors (SSRIs) [4, 5, 8]. Compared with the older tricyclic antidepressant (TCAs), SSRIs 
have a milder adverse drug reaction profile, have a lower risk of severe consequences in 
case of overdosing, and do not require continuous monitoring of blood levels in a number 
of indications [5, 8-10]. Although increasingly prescribed, it was shown in some studies that 
incident antidepressant drug use only increased until the year 2000. Thereafter, the number 
of new users of antidepressants stabilized or even decreased [4, 11]. The discrepancy 
between patterns of prevalence and incidence of antidepressant use was most likely caused 
by an increased recurrent antidepressant use and increased treatment duration over time 
[2, 12].
Although antidepressant use was higher in the older aged, an excessive rise in 
antidepressant use by the older aged was not demonstrated consistently [4, 8, 11, 13]. 
Nevertheless, there are concerns whether the indication to prescribe antidepressants is 
always justified in elderly [14-17]. This patient population is at higher risk for drug-drug 
interactions and adverse drug reactions, as they have a lower drug metabolism, a lower 
renal clearance, have more co-morbidities and use more medications concomitantly [10, 
18, 19]. To minimize the risk of adverse drug reactions in the elderly, an addendum of the 
multidisciplinary guidelines for general practitioners and medical specialists was published 
in 2008. In this guideline, it was recommended to use SSRIs or nortriptyline, instead of the 
other TCAs [20]. However, it is unclear to what extend general practitioners adhere to these 
guidelines. 
The increase in antidepressant use in the last decades was also observed in the 
Netherlands [2, 5, 12, 21]. However, most studies did not yet investigate whether some 
subpopulations were specifically prescribed an increasing number of antidepressants (e.g., 
females or elderly), which is pivotal to estimate what subpopulations are specifically at risk 
to develop particular antidepressant-related adverse effects. For example, it is unknown 
whether the preference of the TCA nortriptyline for the treatment of depression in elderly 
is also reflected by a faster increase in prescribing in this subpopulation [20]. In addition, 
although antidepressants are prescribed for an increasing number of indications, the 
indications for antidepressant use over time are poorly studied. 
We aimed to investigate the (sex- and age-specific) prevalence and incidence of 
antidepressant drug prescribing in a population-based study of specifically middle-aged 
and elderly in the Netherlands. Besides, we aimed to investigate indications for incident 
antidepressant drug prescribing over time. 
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Methods
Setting of the Integrated Primary Care Information database
This study was conducted within the Integrated Primary Care Information (IPCI) database. 
A more detailed description about this database has been published elsewhere [22]. In 
summary, this database is a research database containing the electronic medical records 
of general practitioners (GPs) and currently comprises more than 1.5 million patients in the 
Netherlands. The IPCI database was initiated in 1992 and expanded greatly since then. With 
regard to demographic factors such as age and sex, the distribution of the IPCI population 
is representative of the overall Dutch population [23]. Research in the IPCI database is 
optimal in several ways. First, all Dutch inhabitants are registered with a GP practice, limiting 
selection bias. Second, in the Dutch healthcare system, the GP acts as a gatekeeper between 
primary and secondary care. Medical records of GPs therefore also contain information 
from secondary care. And finally, participating GP practices are not allowed to use additional 
paper-based medical records which makes the electronic database more complete. 
The IPCI database contains information on demographics, symptoms, diagnoses, referrals, 
clinical and laboratory findings, hospitalizations and drug prescriptions. Information on drug 
prescriptions comprises the brand name, generic name, number of pills/capsules/solution, 
prescribed daily dose, and the Anatomical Therapeutic Chemical (ATC) classification code 
[24]. The IPCI database follows the European Union guidelines on the use of medical data for 
medical research and has been validated for the use of pharmacoepidemiological research 
[22]. The current study was approved by The Scientific and Ethical Advisory Board of the IPCI 
project (project number: 12/12). 
Study population
For the current study we included all patients aged 10 years and older with at least one 
year of medical history from the IPCI database. Patients, who had a follow-up of at least 
one year, were followed from start of study (January 1, 1996) until death, loss to follow-up 
or end of the study period (December 31, 2012), whichever came first. For the calculation 
of the incidence rate, patients were censored at the date of their first antidepressant drug 
prescription. 
Study outcome
An antidepressant drug prescription was defined based on the (4-digit) ATC-code “N06A”. 
Antidepressants were classified into antidepressant drug classes (ATC-code: TCA, “N06AA”; 
SSRI, “N06AB”; other, “N06AX”). Amitriptyline (ATC-code: “N06AA09”) and nortriptyline 
(ATC-code: “N06AA10”) were identified based on the individual complete (7-digit) ATC-
codes. Changes in ATC coding were taken into account. For all these categories both 
prevalence and incidence rates were calculated. 
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The yearly prevalence of antidepressant prescriptions was calculated by dividing the 
total number of patients with at least one antidepressant drug prescription by the total 
number of person years in a calendar year. Because of data conversion in different health 
care software systems in 2006, prevalence rates could not be calculated correctly in this 
year. For this reason prevalence rates in this year were interpolated based on the average 
of the surrounding years. 
To calculate the incidence of antidepressant prescribing, we divided the total number 
of patients who were prescribed an antidepressant for the first time during follow-up by 
the total number of person years (PY) within a calendar year. We defined a prescription 
as incident when no antidepressant drug prescription was identified in the one year 
medical history prior to study inclusion. For this analysis, no interpolation was necessary, as 
interpolated results and actual calculated results were similar in 2006. 
The indication of incident antidepressant prescriptions was based on International 
Classification of Primary Care (ICPC) codes [25]. We selected only those indications from 
whom we expected to have sufficient numbers in middle-aged and elderly patients. The 
following indications were considered when identified within 90 days before or after the 
first antidepressant prescription: depression (ICPC code: P03, P76), anxiety (P01, P74), sleep 
disorders (P06), neuropathic pain (N94) and psychosis and schizophrenia (P71, P72, P98). 
When more than one indication was recorded within 90 days around initiation of incident 
antidepressant therapy, the incident antidepressant prescription was considered to be 
prescribed for “multiple indications”. 
Co-factors
Prevalent and incident antidepressant prescribing were studied over time, and stratified by 
sex and different age strata. Strata were defined as such that a sufficient number of patients 
were available in all strata. The following age strata were defined: 10 – 19, 20 – 39, 40 – 59, 
60 – 79 and ≥ 80 years. For the analysis on amitriptyline and nortriptyline, we applied a 
different stratification, as the number of patients treated with amitriptyline or nortriptyline 
≥ 80 years was too low. This age stratum was combined with the patients between the age 
of 70 and 79 years (denoted hereafter as elderly). This group was compared with patients 
between the age of 50 and 69 (denoted hereafter as middle-aged), to compare the patterns 
in middle-aged and elderly patients.
Data analysis
The characteristics of the study population were studied by calculating the number of 
patients in an age group stratified by sex. During follow-up patients were allowed to switch 
age-groups, therefore these numbers exceeded the total number of patients included in the 
study.
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The prevalence and incidence rates were calculated per calendar year. Results were 
presented by calculating the average of the rates per pair of calendar years as in some of 
the subanalyses an insufficient number of prescriptions was available. Rates were calculated 
for all antidepressants together, separately per drug class and separately for amitriptyline 
and nortriptyline. 
We stratified the analyses additionally by sex and age strata. The comparison of 
prevalence and incidence rates over time between different age categories and between 
males and females was conducted using linear regression analysis. As the number of patients 
increased over time, we weighted the analyses for the total number of person years in two 
consecutive years. The comparisons were statistically tested by including a multiplicative 
interaction term between the calendar year and the studied factor (for example, is a rise 
or decrease in prevalent or incident prescribing specific for a particular subpopulation). 
Analyses were conducted with SPSS statistical software (version 21.0, IBM Corporation, 
Armonk, NY). A two-sided p-value below 0.05 was considered statistically significant. 
To study the indications of incident antidepressant prescriptions over time, the total 
number of known indications within a pair of calendar years, as extracted from the study 
population, was considered as 100 percent. The contribution of an individual indication was 
calculated as a percentage relative to the total number of identified indications.
Results
Population characteristics
In total, approximately 1.49 million patients had an age above 10 years during follow-up and 
were included in the study (Table 1). The study population comprised slightly more females 
than males. Females were also more frequently older than 70 years. 
Table 1. Characteristics of the study population.
Females Males
N = 767,492 N = 724,870
Age, years, N (%)
  10 – 19 122,914 (16.0) 127,358 (17.6)
  20 – 29 148,862 (19.4) 137,251 (18.9)
  30 – 39 150,756 (19.6) 146,658 (20.2)
  40 – 49 161,353 (21.0) 159,925 (22.1)
  50 – 59 139,100 (18.1) 137,416 (19.0)
  60 – 69 112,033 (14.6) 109,267 (15.1)
  70 – 79 75,537 (9.8) 64,483 (8.9)
  ≥80 52,391 (6.8) 29,913 (4.1)
The sum of the percentages exceeds the 100 percent and exceeds total number of patients, as participants could change 
age category during follow up. 
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Prevalent antidepressant prescriptions
From 1996 to 2012 (Figure 1a), prevalent antidepressant prescribing doubled (from 35.5 
per 1,000 patients in 1996 – 1997 to 69.8 per 1,000 patients in 2012). The absolute rise in 
prevalence of SSRIs was largest and increased from 18.2 per 1,000 patients in 1996 – 1997 
to 38.4 per 1,000 patients in 2012. In addition, prevalence of TCAs remained stable and the 
prevalence of other antidepressants almost tripled over time. 
In the sex-stratified analysis (Figure 1b), prevalence was higher and increased more over 
time in females than in males (p-value = 0.005). In addition, although prevalence was higher 
in the older aged (Figure 1c), the increase in prevalent prescribing of antidepressants was 
similar over the age strata (p-values > 0.18). This remained similar when stratified by drug 
class (data not shown). In addition, patients aged 70 years and older (the elderly) were 
prescribed more amitriptyline and nortriptyline compared to patients between the age 
of 50 and 69 years (the middle-aged; Figure 1d). In the middle-aged population, the rise 
of prevalent prescribing of nortriptyline was less pronounced than the rise of prevalent 
prescribing of amitriptyline (p-value = 0.003). However, the increase in prevalent prescribing 
was similar for amitriptyline and nortriptyline in the elderly (p-value = 0.51). 
 
Figure 1. Prevalence of antidepressant drug prescribing over time.
a) Prevalence of antidepressant use by drug class. b) Prevalence of antidepressants in men and women. c) Prevalence of 
antidepressant drug prescribing by age strata. d) Prevalence of amitriptyline and nortriptyline in patients between age 50 
and 69 and above 69 years. Data presented as the number of patients with at least one prescription in a calendar year 
per 1000 patients. The dotted part of the line represents the period in which prevalence could not be estimated properly. 
Abbreviations: SSRIs= selective serotonin reuptake inhibitors, TCAs= tricyclic antidepressants. 
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Incident antidepressant prescribing
Until 2000, incident prescribing of antidepressant drugs increased (Figure 2a), but decreased 
thereafter (from 22.6 per 1,000 PY in 2000 – 2001 to 17.1 per 1,000 PY in 2012). Of the 
different antidepressant drug classes, the decrease in incident prescribing of SSRIs was 
strongest, whereas incident prescribing of TCAs increased in more recent years and was 
highest in 2012 (4.3 per 1,000 PY). 
Females had a higher incidence of antidepressant drug prescribing than males (Figure 
2b). The decrease in incidence from 2000 – 2001 onwards was more pronounced in females 
than in males (p-value = 0.014). Furthermore, the incidence of antidepressant prescribing 
was highest in patients > 80 years, but trends over time were similar across the age strata 
(Figure 2c). From 2006 onwards (Figure 2d), incident prescribing of amitriptyline and 
nortriptyline increased both in older adults and elderly, but the difference between the two 
remained similar over time for both age strata (p-values > 0.16). 
Figure 2. Incidence of antidepressant drug prescribing over time.
a) Incidence of antidepressant use by drug class. b) Incidence of antidepressants in men and women. c) Incidence of 
antidepressant drug use by age strata. d) Incidence of amitriptyline and nortriptyline in patients between age 50 and 69 
and above 69 years. Data presented as the total number of incident users per 1,000 person years within a calendar year. 
Abbreviations: SSRIs= selective serotonin reuptake inhibitors, TCAs= tricyclic antidepressants. 
Indication of prescribing 
Indications registered by ICPC codes were recorded for 41 percent of the incident prescrip-
tions during the study period, which decreased from 68 percent in 1996-1997 to 40 percent in 
2012. In this subpopulation, antidepressants were mostly prescribed for depression-related 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Prescription and indication trends  |  39
2.2
disorders. However, this percentage decreased from 65% in 1996 to 47% in 2012 (Figure 
3a). In more recent years, antidepressants were increasingly prescribing for sleep disorders 
and neuropathic pain. The relative decrease of prescribing antidepressants for depression-
related indications was least visible for SSRIs (Figure 3b). Furthermore, depression-related 
indications accounted only for a minor percentage (18% in 2012) of incident TCA prescriptions 
(Figure 3c). TCAs were mostly prescribed for sleep disorders and neuropathic pain (both 
25 – 30 percent in 2012). However, this was different for nortriptyline, which was mostly 
prescribed for depression-related indications (31 percent in 2012; results not presented 
in the figure). Other antidepressants were also increasingly prescribed for indications like 
anxiety and sleep disorders (Figure 3d). Compared with middle-aged adults, elderly were 
more often prescribed antidepressants for indications different than depression (data not 
shown). 
Figure 3. Indication of antidepressant prescribing over time.
a) Indication trends of all antidepressants taken together. b) Indication trends of selective serotonin reuptake inhibitors. 
c) Indications trends of tricyclic antidepressants. d) Indications trends of other antidepressants. Data presented as the 
percentage of drugs prescribed for that indication. 
Abbreviations: SSRIs= selective serotonin reuptake inhibitors, TCAs= tricyclic antidepressants. 
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Discussion
Within this dynamic population-based study, we observed that prevalent antidepressant 
drug prescribing increased between 1996 and 2012, although incident prescribing of 
particularly SSRIs decreased from 2000 onwards. In females, the increase in prevalence and 
the decrease in incidence of antidepressant drug prescribing were more pronounced over 
time. In addition, the prevalence and incidence of antidepressant prescribing were higher in 
the older aged. However, the rise in prevalence and incidence of antidepressant prescribing 
was not different for a specific age-group. Over time, antidepressant drugs (in particular 
TCAs and other antidepressants) were increasingly prescribed for other indications than 
depression-related indications. 
The 1994 edition of the guidelines by the Dutch College of General Practitioners 
stated that pharmacological treatment is only preferred for severe cases of depression 
[26]. However, the revised guidelines, published in 2003, were more reserved regarding 
the use of pharmacological treatment as first choice. This guideline preferred to start with 
non-pharmacological treatment [27]. Within our study population, we observed that the 
prevalence of antidepressants, in particular SSRIs and other antidepressants, increased. At 
least for the group of other antidepressants, the preference of venlafaxine and mirtazapine 
by the multidisciplinary guidelines (version 2008), might have contributed to the increase in 
prevalence of this drug class [20, 28], although the introduction of more antidepressants in 
this drug class on to the market may have contributed as well. In addition, our findings are in 
agreement with other studies conducted in Western populations [4, 11, 12]. Furthermore, 
we observed that from 2000 onwards, there is a trend towards a lower incidence of 
antidepressant prescribing, which is in line with other studies [4, 11]. This was in particular 
the case for the SSRIs. The revised treatment guideline from 2003, which was more reserved 
to initiate pharmacological treatment, might have contributed to the modest decrease in 
incident use [27]. 
The discrepancy between prevalence and incidence trends of antidepressant drug use 
is also described by other studies and is most likely explained by an increase in recurrent 
use and treatment duration [2, 12]. The difference in prevalent and incident prescribing 
over time between males and females has not yet been reported. The indication depression 
to prescribe antidepressants might explain the difference in trends between males and 
females, although we cannot exclude that also other indications (e.g., premenstrual 
syndrome) contributed to the observed difference between males and females [29, 30]. 
Elderly patients are of special interest, as this population has more co-morbidities and 
is at higher risk of polypharmacy, which increases the risk of drug-drug interactions and 
adverse drug reactions [10, 18, 19]. Some of the previous conducted studies showed that 
the increase in antidepressant drug use was mainly in elderly when compared to middle-
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aged adults [8, 13]. However, within our study population, the increase in prevalence and 
the decrease in incidence were similar across different age strata. Similar results were found 
in a study conducted in British Colombia [4]. Since 2008, the interdisciplinary guidelines 
for the treatment of depression recommend nortriptyline instead of amitriptyline for an 
elderly patient diagnosed with depression [20], as nortriptyline has less cardiac side effects 
than other TCAs. However, no larger increase in prevalence and incidence over time was 
observed for nortriptyline relative to amitriptyline, which indicates that there was no 
clear preference for nortriptyline. The difference in indications to prescribe amitriptyline 
and nortriptyline might explain part of the inconsistency with the treatment guidelines. 
For example, amitriptyline is preferred by the guidelines of the Dutch College of General 
Practitioners as a treatment for neuropathic pain [31, 32]. In addition, nortriptyline was 
prescribed more often for depression-related indications than all TCAs together, which fits 
the preference by the treatment guidelines for the treatment of depression in the elderly 
[20]. 
This study has a few strengths and limitations. A strength was the large sample size, 
and the representativeness of the overall Dutch population [23]. The latter strength 
was supported by the similarity of our numbers with prescription numbers from the 
total Dutch population, as collected by the National Healthcare Institute [33]. This study 
was conducted in a general practice database. Thus, we were dependent on the quality 
of patient information registered by the GP. For this reason, the indication of incident 
antidepressants can be misclassified. In addition, the definition of an incident prescription 
was based on non-use during a 1-year period prior to study inclusion. Patients could still use 
an antidepressant prior to this period for which we did not have information. Furthermore, 
we used ICPC codes to define the indication of incident antidepressant drug prescriptions, 
but this could only be defined for a minor proportion of the total population (about 41%). 
A manual validation of free text of the patient records would have been the best approach, 
but because of the large sample size, this was not feasible. The percentage of registered 
indications was similar as published before in the Dutch population [34]. However, their 
time-window around the first antidepressant drug prescription was larger than used in our 
study. Nevertheless, the proportion of missing indications of use is unlikely to be related to 
the type of antidepressant and thus would not have influenced the results. 
In conclusion, we observed that the prevalence of antidepressant prescribing increased 
over time, but incident antidepressant prescribing, and in particular incident SSRI prescribing, 
decreased from 2000 onwards in Dutch primary care. These trends over time were different 
for males and females, but not for different age strata. In addition, the proportion of 
antidepressants prescribed for depression-related indications decreased during the study 
period. 
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Abstract 
Background and purpose: Serotonin reuptake inhibiting antidepressants decrease platelet 
aggregation. This may cause an increased risk of intracerebral hemorrhage. However, the risk 
of subclinical microbleeds, which are highly prevalent in middle-aged and elderly people, is 
unknown. We studied whether serotonin reuptake inhibiting antidepressants increase the 
frequency of cerebral microbleeds and secondarily whether they lower the presence of 
ischemic vascular damage. 
Methods: Within the population-based Rotterdam Study, information on antidepressant 
use was obtained from continuously monitored pharmacy records. Brain MRI was available 
in 4,945 participants (55% women, mean age 64 years) between 2005-2011. We categorized 
antidepressants based on affinity for the serotonin transporter: high, intermediate or 
low. Microbleeds (presence and location) and ischemic lesions (lacunes, white matter 
lesions) were rated on MRI. Logistic and linear regression, adjusted for age, sex, depressive 
symptoms and cardiovascular risk were used to study the association of antidepressants 
with microbleeds, and ischemic vascular lesions. 
Results: Antidepressant use with strong serotonin reuptake inhibition was not associated 
with microbleed presence (odds ratio compared to non-use 1.03, confidence interval 0.75; 
1.39) irrespective of microbleed location in the brain. Exclusion of antithrombotic users or 
persons with cortical infarcts did not change our results. Furthermore, serotonin reuptake 
inhibition was not related to ischemic vascular brain damage. 
Conclusions: In the general population, use of serotonin reuptake inhibiting antidepressants 
is not related to presence of cerebral microbleeds. This strengthens the idea that the platelet 
inhibitor effects of antidepressant drugs with affinity for serotonin are minimal, and further 
supports the safety of SSRIs for non-gastrointestinal bleedings. 
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Introduction
The use of antidepressant medication in the general population has increased considerably 
in the last decades, in particular the use of selective serotonin reuptake inhibitors (SSRIs) [1, 
2]. This increase in SSRI use may be explained by a broadened indication of SSRI, a different 
adverse effect profile and a lower toxicity compared with classic tricyclic antidepressants 
(TCAs) [3-5].
Yet, despite a more favorable adverse effect profile, the use of SSRIs is not entirely risk 
free [6-9]. SSRIs block the reuptake of serotonin by platelets and decrease serotonin platelet 
concentration, which may lead to impaired aggregation and prolonged bleeding times [10-
14]. SSRIs have therefore extensively been studied in relation to intracerebral hemorrhages 
[15-22], and a recent meta-analysis of controlled observational studies showed an increased 
risk of intracerebral hemorrhages in SSRI users compared to non-users [23]. In addition, 
via the same pathophysiological pathway of reducing platelet aggregation, antidepressants 
with a high inhibition for serotonin reuptake may also reduce the risk of ischemic stroke, 
although to date this hypothesis is scarcely supported by literature [15, 16, 21, 24, 25].
Apart from major cerebrovascular events, it has not yet been investigated whether SSRIs 
or strong inhibitors of serotonin reuptake are associated with subclinical cerebrovascular 
lesions, and more particularly with subclinical bleedings. Cerebral microbleeds have 
increasingly been recognized on magnetic resonance imaging (MRI) in stroke patients, and 
mostly in association with larger intracerebral hemorrhages [26-28]. Yet, microbleeds are 
also highly prevalent in the general population, and microbleeds may similarly represent 
bleeding-prone vessels in these people. Support for this is provided in our previous studies 
in which we showed an association between antiplatelet drugs use and the presence of 
cerebral microbleeds in the general population [29, 30]. 
Given the association of microbleeds with symptomatic bleeds and antiplatelet drug use 
we hypothesized that people who use antidepressants with a great inhibition of serotonin 
reuptake may have a higher prevalence of cerebral microbleeds than non-users, and users of 
antidepressant with a low serotonin affinity. Moreover, we secondarily investigated whether 
the use of these drugs is associated with the presence of ischemic vascular damage on MRI, 
in particular a lower frequency of lacunes of presumed vascular origin [31] and lower white 
matter lesions (WML) volume. 
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Methods
Participants
The Rotterdam Study is a prospective population-based cohort study, within Ommoord, 
a suburb in Rotterdam, the Netherlands. The study comprises 14,926 participants, and 
investigates the prevalence, incidence of, and risk factors for diseases in an aging population 
[32]. The study started in 1990 and after baseline examination, follow-up assessments were 
conducted every 4-5 years including interviews and an extensive set of examinations. From 
2005 onwards, brain MRI was embedded within the core protocol of the Rotterdam Study 
to investigate age-related brain changes on imaging [33]. The institutional review board 
approved the study. Between 2005 and 2011, 5,735 participants visiting the study center in 
that period were eligible to undergo a brain MRI. After informed consent was signed, a total 
of 5,074 non-demented people were scanned. After excluding participants in whom MRI 
was not completed (N=72) and scans with low quality (N=57), data on 4,945 participants 
were available for analyses.
Assessment of antidepressant drug use
We determined antidepressant drug use prior to brain MRI based on fully computerized 
pharmacy records from the 7 pharmacies in the Ommoord district. More than 99% of the 
participants have their drug prescriptions filled at these regional pharmacies. Medication 
records were continuously monitored from January 1st 1991 onwards. Records included the 
date of prescribing, the total amount of drug units per prescription, the prescribed daily 
number of units, the product name of the drugs and the Anatomical Therapeutic Chemical 
(ATC) code. The duration of treatment was calculated by counting the number of prescription 
days. The average prescribed daily dose was expressed in standardized defined daily doses 
(DDD) calculated by summing up the total number of prescribed DDDs from all prescriptions 
divided by the total duration.
We classified antidepressants based on their degree of serotonin reuptake inhibition. 
The classification is based on the dissociation constant (Kd) for the serotonin transporter. 
A lower dissociation constant reflects a higher affinity for the serotonin transporter and 
therefore a higher inhibition of serotonin reuptake. Based on previous literature, we 
categorized antidepressants into high (paroxetine, clomipramine, sertraline, duloxetine, 
fluoxetine), intermediate (escitalopram, citalopram, imipramine, fluvoxamine, amitriptyline, 
venlafaxine), and low (desimipramine, opipramol, nortriptyline, doxepin, dosulepin, 
maprotiline, moclobemide, mianserin, trazodone, nefazodone, mirtazapine) degrees of 
serotonin reuptake inhibition [17, 34-38]. 
People who used multiple antidepressants from the different groups were excluded 
from the main analyses (n=268), to secure a pure exposure. These users were considered 
switchers and were analyzed in subsequent analyses.
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Brain MRI and assessments of MRI markers
Brain MRI scans were performed on a 1.5-Tesla MRI scanner (GE Healthcare Milwaukee, 
WI) [33]. Our multisequence MRI protocol included the following scans: T1-weighted, 
proton-density weighted, T2-weighted, and fluid-attenuated inversion recovery (FLAIR) 
[33]. For microbleed detection we used a custom-made accelerated three-dimensional T2*-
weighted gradient-recalled echo sequence with high spatial resolution and long echo-time 
to enhance the detection of microbleeds [39]. Microbleeds were defined as focal areas of 
low signal intensity on T2*-weighted imaging. Their presence, location, and numbers were 
scored by 1 of 5 trained research-physicians, with good intraobserver and interobserver 
agreement [40]. We categorized microbleeds based on their presumed underlying etiology 
into lobar microbleeds (presumably reflective of cerebral amyloid angiopathy [CAA]), and 
deep or infratentorial microbleeds (presumably reflective of hypertensive arteriopathy) 
[39]. Lacunes and cortical infarcts were rated on FLAIR, proton-density-weighted and T1-
weighted sequences by the same raters of microbleeds. Lacunes were defined as focal 
lesions between ≥3mm and <15mm in size [40]. Infarcts showing involvement of grey 
matter were classified as cortical infarcts. Brain tissue was segmented into grey matter, 
white-matter, and cerebrospinal fluid, using validated automated post-processing steps 
that include conventional k-nearest-neighbour brain tissue classifier extended with WML 
segmentation [41, 42].
Assessment of covariables
We addressed potential confounders by characterizing depressive symptoms, cardiovascular 
risk factors and cardiovascular medication use in our study population. Antidepressant drugs 
are mainly prescribed for depressive disorders. Depression has a bidirectional association 
with cardiovascular disease, and cardiovascular disease is related to the presence of 
microbleeds [43, 44].
Presence of depressive symptoms was evaluated using the Center for Epidemiological 
Studies Depression Scale (CESD) [45]. A score of 16 or higher was indicative of participants 
with clinically relevant depressive symptoms. A very high sensitivity for major depression for 
this score was reported in older adults in the Netherlands [46].
Participants’ cardiovascular risk was assessed during the center visit preceding MRI, 
using interview, laboratory, and physical examinations [47]. This included presence of 
diabetes mellitus, smoking status (ever versus never), serum total cholesterol levels, serum 
high-density lipoprotein (HDL) cholesterol levels, and systolic and diastolic blood pressure. 
Finally, use of lipid lowering drugs (C10), antihypertensive drugs (C02, C03, C07, C08, and 
C09), and antithrombotic drugs (B01AA, B01AB, B01AC, and B01AX) was assessed from 
pharmacy records during follow-up before MRI. 
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Statistical analysis
We analyzed the association between use of antidepressants, their degree of serotonin 
reuptake inhibition (high, intermediate, low) with the presence of cerebral microbleeds 
(present versus absent) using multiple logistic regression, taking non-users as reference 
category. Analyses were repeated for microbleeds at different locations in the brain, namely 
strictly lobar regions and deep or infratentorial regions (with or without lobar microbleeds). 
Furthermore, we repeated all analyses using low and intermediate serotonin reuptake 
inhibition antidepressant users as reference category. Switchers were excluded from the 
main analyses and the subsequent analyses were repeated including switchers.  
All analyses were adjusted for age and sex. We additionally adjusted for presence of 
depressive symptoms, diabetes mellitus, smoking, total and HDL cholesterol, systolic and 
diastolic blood pressure, use of lipid-lowering medication, antihypertensive medication, and 
antithrombotic agents. Sensitivity analyses were performed with exclusion of MRI-defined 
cortical infarcts or exclusion of antithrombotic drug users. Moreover, analyses were stratified 
for sex, the exposure was dichotomized based on the duration of treatment (cut-off was 90 
days) and interaction tests with antithrombotic drug users were performed. The average 
prescribed daily dose, expressed in standardized DDD, was also studied dichotomized on 
1.00 DDD as the cut-off to look at an effect of dose.
Furthermore, we studied the association between the degree of serotonin reuptake 
inhibition of antidepressants and the presence of lacunes and WML volume with, 
respectively, multiple logistic and linear regression. People with cortical infarcts were 
excluded from these analyses. Analyses were adjusted for the same factors as described 
above. Analyses of WML volume were additionally adjusted for intracranial volume. WML 
was log-transformed due to the skewed distribution. 
We considered a p-value <0.05 as statistically significant, and analyses were performed 
with a commercially available software program (IBM SPSS Statistics for Windows, Version 
21.0). 
Results 
Characteristics of the study population are presented in Table 1 and Supplementary Table 1. 
Mean age was 64.0 years (SD 11.0) and 2,724 (55.1%) were female. A total of 930 (18.8%) 
persons had a history of antidepressant use before MRI, and 311 (6.2%) had exclusively 
used antidepressants with a high degree of serotonin reuptake inhibition, 304 (6.1%) 
of an intermediate, and 47 (1.0%) antidepressants of a low degree. Among users, 268 
(5.4%) switched between the different antidepressant drug categories. In the total study 
population, 957 (19.4%) had microbleeds, of whom 629 had strictly lobar and 328 deep or 
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infratentorial microbleeds. In the group of antidepressant drug users (n=930), 18.9% had 
microbleeds, which did not significantly differ from the 19.5% in the population of non-
users. Of all participants in our study, lacunes were present in 370 (7.5%), and median WML 
volume was 3.0 ml. 
Table 1. Baseline characteristics of the study population.
N=4,945
Age, years 64.0 (11.0)
Females 2,724 (55.1)
Depressive symptoms 417 (8.6)
Diabetes mellitus 433 (8.9)
Smoking 3,436 (69.8)
Antidepressant drug users 
   High degree of inhibition* 311 (6.2)
   Intermediate degree of inhibition* 304 (6.1)
   Low degree of inhibition*  47 (1.0)
   Switchers 268 (5.4)
Presence of cerebral microbleeds 957 (19.4)
   Strictly lobar 629 (13.6)
   Deep or infratentorial 328 (7.6)
White matter lesion volume, mL 3.0 (1.6 – 6.5)
Lacunes 370 (7.5)
Cortical infarcts 165 (3.3)
Total cholesterol, mmol/L 5.5 (1.1)
High-density lipoprotein cholesterol, mmol/L 1.4 (0.4)
Systolic blood pressure, mmHg 138.9 (21.2)
Diastolic blood pressure, mmHg 82.2 (10.9)
History of lipid lowering drug use 1,185 (24.2)
History of antihypertensive drug use 1,696 (34.6)
History of antithrombotic drug use 1,415 (28.6)
Values represent mean (standard deviation) or number (percentage). White matter lesion volume is represented as 
median (interquartile range). * Degree of serotonin reuptake inhibition: High=paroxetine, clomipramine, sertraline, 
duloxetine, fluoxetine. Intermediate = escitalopram, citalopram, impramine, fluvoxamine, amitriptyline, venlafaxine. 
Low = desimipramine, opipramol, nortriptyline, doxepin, dosulepin, maprotiline, moclobemide, mianserin, trazodone, 
nefazodone, mirtazapine.
Compared to non-use, the use of antidepressants with a high serotonin reuptake 
inhibitory potential was not associated with cerebral microbleed presence (age, sex-adjusted 
odds ratio [OR] 1.03, 95% CI 0.75; 1.39). In addition, no association was found for low (OR 
0.76, 95% CI 0.36; 1.62) or intermediate (OR 1.04, 95% CI 0.77; 1.39) serotonin affinity 
antidepressants. Compared to non-use, the use of antidepressant medication with either 
high, intermediate, or low affinity for serotonin was neither related to lobar, nor to deep or 
infratentorial microbleeds (Table 2). Additionally, no association between antidepressant 
use and microbleeds was found for people who switched between different antidepressant 
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drugs (OR 0.95, 95% CI 0.68; 1.33). Additional adjustments for cardiovascular risk factors, 
cardiovascular medication and depressive symptoms did not change any of the results 
significantly (Table 2). Excluding participants with MRI-defined cortical infarcts (n=158), 
and excluding ever antithrombotic drug users (n=1,326) also did not materially change our 
results (data not shown). Moreover, the exposure split by duration and average prescribed 
daily dose of antidepressant drug treatment and stratification by gender did not significantly 
change our results (data not shown). Effect modification of antidepressant drug exposure by 
antithrombotic drugs was not present (p=0.96). 
We did not find a higher frequency of cerebral microbleeds, irrespective of their location 
in the brain, when comparing the high affinity group with the combined intermediate and 
low affinity group (OR 1.03, 95% CI 0.68; 1.56) (Table 3). 
Finally, we did not find a lower frequency of lacunes (OR 1.14, 95% CI 0.67; 1.94) nor a 
smaller WML volume (mean difference of WML volume 0.06, 95% CI -0.03; 0.15) for use of 
antidepressants with a high serotonin reuptake inhibition potential compared to non-use, 
neither did we find a relation when investigating the use of low and intermediate degree of 
serotonin reuptake inhibition (Table 4). 
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Table 4. Degree of serotonin reuptake inhibition for antidepressant drugs and the presence of lacunes 
and white matter lesion volume. 
Degree of serotonin 
reuptake inhibition
Lacunes White matter  
lesion volume
n / N Odds ratio 
(95%CI)
N Difference in mean 
(95% CI)
Model 1
Non-use 260 / 3,888 1.00 (Reference) 3,881 0.00 (Reference)
Low 3 / 45 0.82 (0.25; 2.74) 45 -0.05 (-0.28; 0.18)
Intermediate 23 / 288 1.20 (0.76; 1.90) 288 0.08 (-0.02; 0.17)
High 16 / 298 1.14 (0.67; 1.94) 298 0.06 (-0.03; 0.15)
Model 2
Non-use 247 / 3,728 1.00 (Reference) 3,722 0.00 (Reference)
Low 3 / 43 0.89 (0.26; 3.02) 43 -0.04 (-0.27; 0.19)
Intermediate 22 / 275 1.13 (0.70; 1.82) 275 0.06 (-0.03; 0.16)
High 15 / 285 1.05 (0.60; 1.86) 285 0.06 (-0.03; 0.15)
Lacunes: values represent odds ratios for lacunes in antidepressant drug users with low, medium, and high affinity for 
serotonin compared to non-users. White matter lesions volume: values represent differences in mean log transformed 
white matter lesion volumes (ml) in antidepressant drug users with low, medium, and high affinity for serotonin compared 
to non-users. Model 1: adjusted for age and sex. Model 2: adjusted for age, sex, depression, diabetes, smoking, total 
and HDL cholesterol, systolic and diastolic blood pressure, ever use of lipid-lowering drugs, antihypertensive drugs, and 
antithrombotic drugs. Number of cases/total population deviate from model 1, as we performed a complete caseset 
analysis. White matter lesion volume analyses were additionally adjusted for intracranial volume and participants with 
unreliable white matter lesion segmentations were excluded from analyses. 
Abbreviations:  n= number of cases, N= total population within the exposure category.
Discussion
In the general population, we did not find an association between antidepressant drug use 
with a greater inhibition of serotonin reuptake and the presence of cerebral microbleeds. In 
addition, the degree of serotonin reuptake inhibition was not associated with presence of 
lacunes or WML volume. 
Microbleeds are thought to precede the onset of large symptomatic hemorrhages, and 
may thus reflect a clinically relevant preclinical imaging marker, although evidence from 
longitudinal studies is still limited [26, 48, 49]. The novelty of our study lays in the fact that 
we investigated the use of SSRIs in relation to subclinical hemorrhagic brain lesions in the 
general population, in contrast to clinical studies investigating symptomatic hemorrhage. 
We did not observe an association between degree of serotonin reuptake inhibition and 
the presence of microbleeds. This is in line with the majority of previous studies on SSRIs 
and symptomatic brain hemorrhages [15, 18, 20], although a recent meta-analysis did find 
an increased risk of brain hemorrhages in SSRI users (OR cohort studies 1.68, 95% CI 1.04; 
2.51) [23]. As a methodological consideration; heterogeneity in sample size, quality of the 
individual studies and different approaches to handle the influence of confounding may 
have influenced the validity of the meta-analysis to a certain degree [50]. 
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SSRIs might increase the risk of clinical or subclinical bleedings via the following main 
biological mechanism. Damage to endothelial layers leads to activation of hemostatic 
mechanisms, and platelets adhere to damaged vessel walls. Intracellular serotonin 
is subsequently released into the blood stream and promotes clot formation and 
vasoconstriction at the site of injury. SSRIs inhibit the reuptake of serotonin by platelets 
from the blood, reduce intracellular serotonin concentrations, thereby decrease platelet 
aggregation and increase the risk of bleeding [12, 13]. Moreover, a second mechanism 
proposes that some SSRIs may inhibit cytochrome 450 (CYP) enzymes such as CYP 1A2, 2D6, 
3A4 and 2C9. This may increase the bleeding risk by inhibition of the metabolism of certain 
drugs that have anticoagulant properties such as NSAIDS and antithrombotic drugs [13, 14]. 
Nonetheless, for both mechanisms we could argue that diminishing intraplatelet 
serotonin levels only affects hemostasis to a limited extent, and thus that remaining platelet 
function is sufficient to halt significant bleeding. Depletion of serotonin levels in platelets 
may well be compensated for by other adequately working hemostatic mechanisms. This 
would partly explain why SSRI use was more consistently associated with extra-cranial 
bleeds, in particular gastro-intestinal bleedings. Here, SSRI use increases serotonin levels 
and stimulates the production of gastric acid, which increases the risk of gastrointestinal 
bleedings. Bleeding complications may therefore be induced by a third mechanism which 
does not necessarily involve platelet dysfunction [14]. 
No association was found for antidepressants with an affinity for serotonin with 
microbleeds in either lobar or deep or infratentorial regions of the brain. Although 
microbleeds at both locations are representative of bleeding-prone vessels, their etiologies 
differ. Microbleeds in lobar regions are more likely to result from blood leaking from 
destructed vessel walls containing amyloid, whereas deep or infratentorial microbleeds most 
likely represent hemosiderin deposits as a consequence of hypertensive arteriopathy [28, 
40, 43, 51]. Our findings suggest that regardless of the underlying pathology, the decrease of 
intracellular serotonin platelets caused by antidepressants with a strong serotonin reuptake 
potential is insufficient to increase the frequency of small, asymptomatic bleedings.    
Finally, we did not find a protective effect of antidepressant drugs, with a high affinity for 
the serotonin transporter, on ischemic vascular brain lesions. This is in line with findings from 
previous studies in patients with ischemic stroke [15, 21], and strengthens the idea that the 
platelet inhibitor effects of antidepressant drug with affinity for serotonin are minimal. Two 
previous studies showed an increased risk of ischemic stroke in current SSRI users [16, 24]. 
This increased risk could be explained by a different biological mechanism which postulates 
that serotonin induces vasoconstriction of large vessel, and may lead to thromboembolic 
ischemic stroke in the presence of atherosclerosis [52]. However, in our study, we focused 
on silent ischemic vascular lesions, involving the small cerebral arteries, which are typically 
not caused by thromboembolic events. 
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Strengths of our study are the large sample size, population-based character of our study, 
and the prospectively gathered electronic pharmacy records which we used to determine 
antidepressant drug use. Based on a 19.5% prevalence of microbleeds in unexposed subjects, 
with a two-sided significance of 0.05, we had sufficient power (80%) to detect an odds 
ratio of 1.22 or greater. Less strong associations may not have been detected in our study, 
although based on the recent meta-analysis on SSRIs and symptomatic brain hemorrhages 
we would expect an estimate of at least this magnitude for subclinical bleedings [23]. 
Some limitations of our study need to be considered. The cross-sectional design of our 
study limits our conclusions on a causal pathway. MRI does not provide information on the 
timing of when cerebral microbleeds occurred, as cerebral microbleeds remain visible in 
the brain for an undefined period. Therefore, there is a possibility that cerebral microbleeds 
occurred before antidepressant use was initiated. This may have led to an underestimation 
of the true association presented due to non-differential misclassification of SSRI users, 
and further longitudinal investigations are warranted. Furthermore, confounding by 
indication and contra-indication poses a problem in our observational study. Depression, 
the most important indication to prescribe antidepressants, has a bidirectional association 
with cardiovascular disease, and cardiovascular diseases are associated with an increased 
number of microbleeds. Moreover, TCAs are relatively contra-indicated for patients with 
cardiovascular disease. We minimized these forms of confounding by adjusting for presence 
of depressive symptoms, cardiovascular risk factors, and cardiovascular medication. Also, 
we reclassified the antidepressant drugs based on their their affinity to the serotonin 
reuptake transporter. Although we aimed to address all potential confounders in our study, 
residual confounding cannot be ruled out and may have affected our results to an extent 
that associations may have been overestimated. 
In conclusion, this study adds important information to the previous reports on 
antidepressant drug use and bleeding risk. We report that, in the general population, the 
use of antidepressant drugs that inhibit serotonin reuptake is not related to the presence 
of cerebral microbleeds. This further supports the safety of these antidepressants for non-
gastrointestinal bleedings. Since these results are cross-sectional, further longitudinal 
research regarding antidepressant drug use and the risk of microbleeds in relation to major 
intracerebral hemorrhage is of high interest. 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Prevalent cerebral microbleeds  |  85
3.1
References 
1. Parabiaghi A, Franchi C, Tettamanti M, Barbato A, D’Avanzo B, Fortino I, et al. Antidepressants 
utilization among elderly in Lombardy from 2000 to 2007: dispensing trends and appropriateness. Eur 
J Clin Pharmacol. 2011 Oct;67(10):1077-83.
2. Sonnenberg CM, Deeg DJ, Comijs HC, van Tilburg W, Beekman AT. Trends in antidepressant use in 
the older population: results from the LASA-study over a period of 10 years. J Affect Disord. 2008 
Dec;111(2-3):299-305.
3. Olfson M, Marcus SC, Pincus HA, Zito JM, Thompson JW, Zarin DA. Antidepressant prescribing 
practices of outpatient psychiatrists. Arch Gen Psychiatry. 1998 Apr;55(4):310-6.
4. Chemali Z, Chahine LM, Fricchione G. The use of selective serotonin reuptake inhibitors in elderly 
patients. Harvard Rev Psychiat. [Review]. 2009;17(4):242-253.
5. MacGillivray S, Arroll B, Hatcher S, Ogston S, Reid I, Sullivan F, et al. Efficacy and tolerability of selective 
serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary 
care: systematic review and meta-analysis. BMJ. 2003 May 10;326(7397):1014.
6. Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J. Antidepressant use and risk of 
adverse outcomes in older people: population based cohort study. BMJ. 2011;343:d4551.
7. Lewis JD, Strom BL, Localio AR, Metz DC, Farrar JT, Weinrieb RM, et al. Moderate and high affinity 
serotonin reuptake inhibitors increase the risk of upper gastrointestinal toxicity. Pharmacoepidemiol 
Drug Saf. 2008 Apr;17(4):328-35.
8. Gartner R, Cronin-Fenton D, Hundborg HH, Pedersen L, Lash TL, Sorensen HT, et al. Use of selective 
serotonin reuptake inhibitors and risk of re-operation due to post-surgical bleeding in breast cancer 
patients: a Danish population-based cohort study. BMC Surgery. 2010;10:3.
9. Verdel BM, Souverein PC, Meenks SD, Heerdink ER, Leufkens HG, Egberts TC. Use of serotonergic 
drugs and the risk of bleeding. Clin Pharmacol Ther. 2011 Jan;89(1):89-96.
10. Maurer-Spurej E, Pittendreigh C, Solomons K. The influence of selective serotonin reuptake inhibitors 
on human platelet serotonin. Thromb Haemost. 2004 Jan;91(1):119-28.
11. Bismuth-Evenzal Y, Gonopolsky Y, Gurwitz D, Iancu I, Weizman A, Rehavi M. Decreased serotonin 
content and reduced agonist-induced aggregation in platelets of patients chronically medicated with 
SSRI drugs. J Affect Disord. 2012 Jan;136(1-2):99-103.
12. Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B. Paroxetine decreases platelet 
serotonin storage and platelet function in human beings. Clin Pharmacol Ther. 2000 Oct;68(4):435-
442.
13. Padma L, Ranjani R, Rohini ST. Selective serotonin reuptake inhibitors and the risk of bleeding. Int J 
Basic Clin Pharmacol. 2013;2(3):272-274.
14. Andrade C, Sandarsh S, Chethan KB, Nagesh KS. Serotonin reuptake inhibitor antidepressants and 
abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry. 
2010 Dec;71(12):1565-1575.
15. Bak S, Tsiropoulos I, Kjaersgaard JO, Andersen M, Mellerup E, Hallas J, et al. Selective serotonin 
reuptake inhibitors and the risk of stroke - a population-based case-control study. Stroke. 2002 
Jun;33(6):1465-1473.
16. Chen Y, Guo JJ, Li H, Wulsin L, Patel NC. Risk of cerebrovascular events associated with antidepressant 
use in patients with depression: a population-based, nested case-control study. Ann Pharmacother. 
2008 Feb;42(2):177-84.
17. Chen Y, Guo JJ, Patel NC. Hemorrhagic stroke associated with antidepressant use in patients with 
depression: does degree of serotonin reuptake inhibition matter? Pharmacoepidemiol Drug Saf. 2009 
Mar;18(3):196-202.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
86  |  Chapter 3.1
18. de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S. Intracranial haemorrhage and use of selective serotonin 
reuptake inhibitors. Brit J Clin Pharmaco. 2000 Jul;50(1):43-47.
19. Douglas I, Smeeth L, Irvine D. The use of antidepressants and the risk of haemorrhagic stroke: a 
nested case control study. Brit J Clin Pharmaco. 2011 Jan;71(1):116-120.
20. Kharofa J, Sekar P, Haverbusch M, Moomaw C, Flaherty M, Kissela B, et al. Selective serotonin reuptake 
inhibitors and risk of hemorrhagic stroke. Stroke. 2007 Nov;38(11):3049-3051.
21. Pan A, Okereke OI, Sun Q, Logroscino G, Manson JE, Willett WC, et al. Depression and incident stroke 
in women. Stroke. 2011 Oct;42(10):2770-5.
22. Smoller JW, Allison M, Cochrane BB, Curb JD, Perlis RH, Robinson JG, et al. Antidepressant use and risk 
of incident cardiovascular morbidity and mortality among postmenopausal women in the Women’s 
Health Initiative study. Arch Intern Med. 2009 Dec 14;169(22):2128-39.
23. Hackam DG, Mrkobrada M. Selective serotonin reuptake inhibitors and brain hemorrhage: a meta-
analysis. Neurology. 2012 Oct 30;79(18):1862-5.
24. Trifiro G, Dieleman J, Sen EF, Gambassi G, Sturkenboom MC. Risk of ischemic stroke associated with 
antidepressant drug use in elderly persons. J Clin Psychopharmacol. 2010 Jun;30(3):252-8.
25. Lee YC, Lin CH, Lin MS, Lin JW, Chang CH, Lai MS. Effects of selective serotonin reuptake inhibitors 
versus tricyclic antidepressants on cerebrovascular events: a nationwide population-based cohort 
study. J Clin Psychopharmacol. 2013 Dec;33(6):782-9.
26. Charidimou A, Kakar P, Fox Z, Werring DJ. Cerebral microbleeds and recurrent stroke risk: systematic 
review and meta-analysis of prospective ischemic stroke and transient ischemic attack cohorts. 
Stroke. 2013 Apr;44(4):995-1001.
27. Gregoire SM, Brown MM, Kallis C, Jager HR, Yousry TA, Werring DJ. MRI detection of new microbleeds 
in patients with ischemic stroke: five-year cohort follow-up study. Stroke. 2010 Jan;41(1):184-6.
28. Smith EE, Nandigam KR, Chen YW, Jeng J, Salat D, Halpin A, et al. MRI markers of small vessel disease 
in lobar and deep hemispheric intracerebral hemorrhage. Stroke. 2010 Sep;41(9):1933-8.
29. Vernooij MW, Haag MD, van der Lugt A, Hofman A, Krestin GP, Stricker BH, et al. Use of antithrombotic 
drugs and the presence of cerebral microbleeds the Rotterdam Scan Study. Arch Neurol. 2009 
Jun;66(6):714-720.
30. Darweesh SK, Leening MJ, Akoudad S, Loth DW, Hofman A, Ikram MA, et al. Clopidogrel use is 
associated with an increased prevalence of cerebral microbleeds in a stroke-free population: the 
Rotterdam Study. J Am Heart Assoc. 2013 Oct;2(5):e000359.
31. Wardlaw JM, Smith C, Dichgans M. Mechanisms of sporadic cerebral small vessel disease: insights 
from neuroimaging. Lancet Neurol. 2013 May;12(5):483-497.
32. Hofman A, Darwish Murad S, Duijn CM, Franco OH, Goedegebure A, Ikram MA, et al. The Rotterdam 
Study: 2014 objectives and design update. Eur J Epidemiol. 2013;28(11):889-926.
33. Ikram MA, Van Der Lugt A, Niessen WJ, Krestin GP, Koudstaal PJ, Hofman A, et al. The Rotterdam Scan 
Study: design and update up to 2012. Eur J Epidemiol. 2011;26(10):811-824.
34. Meijer WE, Heerdink ER, Nolen WA, Herings RM, Leufkens HG, Egberts AC. Association of risk of 
abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch Intern Med. 
2004 Nov 22;164(21):2367-2370.
35. van Walraven C, Mamdani MM, Wells PS, Williams JI. Inhibition of serotonin reuptake by 
antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. 
Brit Med J. 2001 Sep 22;323(7314):655-658.
36. Tatsumi M, Groshan K, Blakely RD, Richelson E. Pharmacological profile of antidepressants and related 
compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58.
37. Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding 
profile of escitalopram and R-fluoxetine. Biol Psychiatry. 2001 Sep 1;50(5):345-50.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Prevalent cerebral microbleeds  |  87
3.1
38. Kuo F, Gillespie TA, Kulanthaivel P, Lantz RJ, Ma TW, Nelson DL, et al. Synthesis and biological activity 
of some known and putative duloxetine metabolites. Bioorg Med Chem Lett. 2004;14(13):3481-3486.
39. Vernooij MW, Ikram MA, Wielopolski PA, Krestin GP, Breteler MM, van der Lugt A. Cerebral 
microbleeds: Accelerated 3D T2*-weighted GRE MR imaging versus conventional 2D T2*-weighted 
GRE MR imaging for detection. Radiology. 2008 Jul;248(1):272-277.
40. Vernooij MW, van der Lugt A, Ikram MA, Wielopolski PA, Niessen WJ, Hofman A, et al. Prevalence and 
risk factors of cerebral microbleeds - the Rotterdam Scan Study. Neurology. 2008 Apr 1;70(14):1208-
1214.
41. de Boer R, Vrooman HA, van der Lijn F, Vernooij MW, Ikram MA, van der Lugt A, et al. White matter 
lesion extension to automatic brain tissue segmentation on MRI. Neuroimage. 2009 May 1;45(4):1151-
1161.
42. Vrooman HA, Cocosco CA, van der Lijn F, Stokking R, Ikram MA, Vernooij MW, et al. Multi-spectral 
brain tissue segmentation using automatically trained k-Nearest-Neighbor classification. Neuroimage. 
2007 Aug 1;37(1):71-81.
43. Poels MM, Vernooij MW, Ikram MA, Hofman A, Krestin GP, van der Lugt A, et al. Prevalence and 
risk factors of cerebral microbleeds: an update of the Rotterdam Scan Study. Stroke. 2010 Oct;41(10 
Suppl):S103-6.
44. Rumsfeld JS, Ho PM. Depression and cardiovascular disease - a call for recognition. Circulation. 2005 
Jan 25;111(3):250-253.
45. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl 
Psych Meas. 1977 June 1, 1977;1(3):385-401.
46. Blazer D, Burchett B, Service C, George LK. The association of age and depression among the elderly: 
an epidemiologic exploration. Journal of Gerontology. 1991 Nov;46(6):M210-5.
47. Leening MJG, Kavousi M, Heeringa J, van Rooij FJA, Verkroost-van Heemst J, Deckers JW, et al. Methods 
of data collection and definitions of cardiac outcomes in the Rotterdam Study. Eur J Epidemiol. 2012 
Mar;27(3):173-185.
48. Soo YO, Siu DY, Abrigo J, Yu S, Ng N, Ahuja AT, et al. Risk of intracerebral hemorrhage in patients with 
cerebral microbleeds undergoing endovascular intervention. Stroke. 2012 Jun;43(6):1532-6.
49. Sun S, Gao P, Sui B, Xue J, Wang H, Wang Q, et al. Association between cerebral microbleeds and the 
first onset of intracerebral hemorrhage - a 3.0 T MR study. Acta Radiologica. 2012 Mar 1;53(2):203-7.
50. McGrath ER, O’Donnell MJ. Estimating treatment effects in observational studies. Neurology. 2012 
Oct 30;79(18):1844-5.
51. Fazekas F, Kleinert R, Roob G, Kleinert G, Kapeller P, Schmidt R, et al. Histopathologic analysis of foci 
of signal loss on gradient-echo T2*-weighted MR images in patients with spontaneous intracerebral 
hemorrhage: evidence of microangiopathy-related microbleeds. AJNR Am J Neuroradiol. 1999 
Apr;20(4):637-42.
52. Ramasubbu R. Cerebrovascular effects of selective serotonin reuptake inhibitors: a systematic review. 
J Clin Psychiatry. 2004 Dec;65(12):1642-53.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
88  |  Chapter 3.1
Su
pp
le
m
en
ta
ry
 T
ab
le
 1
. B
as
el
in
e 
ch
ar
ac
te
ri
sti
cs
 o
f t
he
 s
tu
dy
 p
op
ul
ati
on
. 
D
eg
re
e 
of
 s
er
ot
on
in
 r
eu
pt
ak
e 
in
hi
bi
ti
on
N
on
-u
se
rs
N
=4
,0
15
Lo
w
*
N
=4
7
In
te
rm
ed
ia
te
*
N
=3
04
H
ig
h*
 
N
= 
31
1
A
ge
, y
ea
rs
64
.0
 (1
1.
0)
68
.5
 (1
1.
2)
65
.7
 (1
1.
5)
61
.4
 (9
.7
)
Fe
m
al
es
 
2,
10
0 
(5
2.
3)
31
 (6
6.
0)
20
0 
(6
5.
8)
20
3 
(6
5.
3)
D
ep
re
ss
iv
e 
sy
m
pt
om
s 
19
4 
(4
.9
)
10
 (2
1.
7)
46
 (1
5.
4)
69
 (2
2.
2)
D
ia
be
te
s 
m
el
lit
us
33
7 
(8
.5
)
3 
(6
.5
)
32
 (1
0.
6)
28
 (9
.2
)
Sm
ok
in
g
2,
77
7 
(6
9.
4)
29
 (6
3.
0)
21
0 
(6
9.
8)
22
7 
(7
3.
2)
Pr
es
en
ce
 o
f c
er
eb
ra
l m
ic
ro
bl
ee
ds
78
1 
(1
9.
5)
9 
(1
9.
1)
65
 (2
1.
4)
53
 (1
7.
0)
   
St
ri
ct
ly
 lo
ba
r 
51
1 
(1
3.
6)
7 
(1
5.
6)
42
 (1
4.
9)
33
 (1
1.
3)
   
D
ee
p 
or
 in
fr
at
en
to
ri
al
 
27
0 
(7
.7
)
2 
(5
.0
)
23
 (8
.8
)
20
 (7
.2
)
W
hi
te
 m
att
er
 le
si
on
 v
ol
um
e,
 m
L
2.
9 
(1
.6
 –
 6
.4
)
4.
3 
(1
.8
 –
 8
.0
)
3.
4 
(1
.9
 –
 8
.5
)
2.
6 
(1
.5
 –
 5
.3
)
La
cu
ne
s 
29
7 
(7
.4
)
3 
(6
.4
)
29
 (9
.5
)
20
 (6
.4
)
Co
rti
ca
l i
nf
ar
ct
s 
12
7 
(3
.2
)
2 
(4
.3
)
16
 (5
.3
)
13
 (4
.2
)
To
ta
l c
ho
le
st
er
ol
, m
m
ol
/L
5.
5 
(1
.1
)
5.
5 
(1
.1
)
5.
6 
(1
.1
)
5.
7 
(1
.1
)
H
ig
h-
de
ns
it
y 
lip
op
ro
te
in
 c
ho
le
st
er
ol
, m
m
ol
/L
1.
4 
(0
.4
)
1.
4 
(0
.3
)
1.
5 
(0
.5
)
1.
4 
(0
.4
)
Sy
st
ol
ic
 b
lo
od
 p
re
ss
ur
e,
 m
m
H
g
13
9.
4 
(2
1.
2)
13
5.
5 
(1
7.
0)
13
9.
6 
(2
2.
0)
13
4.
8 
(2
0.
5)
D
ia
st
ol
ic
 b
lo
od
 p
re
ss
ur
e,
 m
m
H
g
82
.3
 (1
0.
9)
80
.1
 (9
.6
)
82
.0
 (1
1.
4)
81
.8
 (1
0.
5)
H
is
to
ry
 o
f l
ip
id
 lo
w
er
in
g 
dr
ug
 u
se
92
7 
(2
3.
3)
17
 (3
6.
2)
86
 (2
8.
4)
85
 (2
7.
3)
H
is
to
ry
 o
f a
nti
hy
pe
rt
en
si
ve
 d
ru
g 
us
e
1,
31
5 
(3
2.
8)
27
 (5
7.
4)
14
2 
(4
6.
9)
10
8 
(3
4.
8)
H
is
to
ry
 o
f a
nti
th
ro
m
bo
ti
c 
dr
ug
 u
se
1,
11
0 
(2
7.
6)
15
 (3
1.
9)
11
6 
(3
8.
2)
85
 (2
7.
3)
Va
lu
es
 r
ep
re
se
nt
 m
ea
n 
(s
ta
nd
ar
d 
de
vi
ati
on
) 
or
 n
um
be
r 
(p
er
ce
nt
ag
e)
. W
hi
te
 m
att
er
 le
si
on
 v
ol
um
e 
is
 r
ep
re
se
nt
ed
 a
s 
m
ed
ia
n 
(in
te
rq
ua
rti
le
 r
an
ge
).
 *
 D
eg
re
e 
of
 s
er
ot
on
in
 r
eu
pt
ak
e 
in
hi
bi
ti
on
: H
ig
h 
= 
pa
ro
xe
ti
ne
, c
lo
m
ip
ra
m
in
e,
 s
er
tr
al
in
e,
 d
ul
ox
eti
ne
, fl
uo
xe
ti
ne
. I
nt
er
m
ed
ia
te
 =
 e
sc
it
al
op
ra
m
, c
it
al
op
ra
m
, i
m
pr
am
in
e,
 fl
uv
ox
am
in
e,
 a
m
it
ri
pt
yl
in
e,
 v
en
la
fa
xi
ne
. L
ow
 =
 
de
si
m
ip
ra
m
in
e,
 o
pi
pr
am
ol
, n
or
tr
ip
ty
lin
e,
 d
ox
ep
in
, d
os
ul
ep
in
, m
ap
ro
ti
lin
e,
 m
oc
lo
be
m
id
e,
 m
ia
ns
er
in
, t
ra
zo
do
ne
, n
ef
az
od
on
e,
 m
ir
ta
za
pi
ne
.
3.2 
Antidepressant use is associated with an increased 
risk of developing microbleeds
Saloua Akoudad*, Nikkie Aarts*, Raymond Noordam, M. Arfan Ikram, Henning Tiemeier, 
Albert Hofman, Bruno H. Stricker, Meike W. Vernooij, Loes E. Visser 
*Authors contributed equally
Accepted for publication in Stroke
3.3 
Use of selective serotonin reuptake inhibitors 
and sleep quality: a population-based study
Nikkie Aarts, Lisette A. Zuurbier, Raymond Noordam, Albert Hofman, 
Henning Tiemeier, Bruno H. Stricker, Loes E. Visser
Submitted 
3.4 
Antidepressants and the risk of hyponatremia: 
a population-based study 
Nikkie Aarts, Jan C. van Blijderveen, Eline M. Rodenburg, Raymond Noordam, 
Miriam C. Sturkenboom, Bruno H. Stricker, Loes E. Visser
In preparation

3.5 
Use of selective serotonin reuptake inhibitors and bone 
mineral density change: a population-based longitudinal 
study in middle-aged and elderly individuals
Annelies C. Ham*, Nikkie Aarts*, Raymond Noordam, Fernando Rivadeneira, 
Gijsbertus Ziere, Carola M. Zillikens, Henning Tiemeier, Nathalie van der Velde, 
Albert Hofman, André G. Uitterlinden, Loes E. Visser, Bruno H. Stricker
*contributed equally 
Submitted
4
General discussion
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
146  |  Chapter 4
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
General discussion  |  147
4
In this chapter, we will discuss the main findings of this thesis and put them into a broader 
perspective. We aimed to characterize use of antidepressants (chapter 2) and their possible 
unintended effects (chapter 3) in daily practice in an ageing population. Furthermore, some 
important methodological considerations which we encountered will be discussed. Finally, 
we will try to translate our results to implications for clinical practice and provide some 
directions for future research. 
Main findings 
Characteristics of antidepressant use in daily practice
Use of antidepressants – especially selective serotonin reuptake Inhibitors (SSRIs) – 
increased excessively in the last decades [1-3]. Within the Rotterdam Study (chapter 
2.1) and with data from the Integrated Primary Care Information database (IPCI [chapter 
2.2]), we also demonstrated a steep increase in antidepressant use in the period between 
1991 and 2012. Prevalent antidepressant use doubled during this period and the steepest 
increase was observed for use of SSRIs. In line, first choice of treatment shifted from tricyclic 
antidepressants (TCAs) to SSRIs and other antidepressants in later years. Moreover, the 
prevalence was even higher in the older age categories. Previously, concerns have been 
raised regarding these high rates of antidepressant use in the population. It has been 
hypothesized that antidepressants are too easily prescribed for indications such as mild 
depressive symptoms and other off-label indications, without any sound scientific evidence 
[4, 5]. In contrast, better adherence to the treatment guidelines – which request long 
term treatment – could also explain the increased prevalence [1, 6]. Therefore, we studied 
multiple characteristics of antidepressant use which could possibly explain the trends in 
prevalence. 
We found that the incidence of antidepressant use over the years did not explain the 
patterns of prevalent prescribing. Incidence rates in chapter 2.1 decreased over time, but 
may be biased by a saturation effect or depletion of susceptibles in an inception cohort 
such as the Rotterdam Study population. However, incidence rates of antidepressant use 
also decreased in the dynamic patient population of IPCI as reported in chapter 2.2, and 
previous literature also reported a declining or stable incidence over the years [7-9]. Next, 
an extension of the indications for antidepressant use to more chronic conditions might 
explain the increasing prevalence. In chapter 2.2, indications for treatment changed over 
the years as antidepressants were increasingly prescribed for sleeping disorders, multiple 
indications and neuropathic pain (only in TCAs). In contrast, the indication ‘depression’ was 
less commonly registered in later years. 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
148  |  Chapter 4
However, given that indications based on diagnostic codes were only registered in 41% 
of antidepressant users in chapter 2.2, we also studied indications for antidepressant use 
based on self-report in chapter 2.3. Indications registered with diagnostic codes in general 
practitioners’ healthcare databases may be incomplete because of diagnostic uncertainty, 
off-label drug use or subthreshold psychiatric symptoms which were not registered 
or may be difficult to recognize from free text in automated medical records [10-14]. In 
chapter 2.3, depression was still most frequently mentioned as indication for treatment 
in our study (based on data between 1997 and 2008). However, especially in TCA users 
the indication profile was very heterogeneous with depression, stress, sleeping disorders 
and pain commonly reported as possible indication for treatment. For SSRIs and other 
antidepressants, the majority of users reported psychiatric symptoms such as depression, 
anxiety, stress and sleep disorders. Furthermore, almost all indications were associated 
with a statistically significantly higher presence of depressive symptoms assessed with the 
Center for Epidemiological Center Depression Scale (CES-D) when compared to non-users. 
This suggests that these symptoms are highly correlated or often occur concomitantly [15-
18]. Previous studies already established that combinations of mental complaints, multi-
morbidity, psychosocial problems and social distress are important reasons to prescribe 
antidepressants [4, 19-22]. Especially in our middle-aged and elderly study population – 
with their potential accumulation of life events and physical impairment – these could be 
important reasons to prescribe antidepressants. A possible shift to prescribing for general 
mental and physical health problems and other (off-label) indications could contribute to 
the increased prevalence of antidepressant use over the years [4, 5, 21]. However, more 
longitudinal patient-specific information is needed to draw firm conclusions. 
An increased duration of treatment might also explain the increased prevalence of 
antidepressant use [3, 23]. Guidelines recommend at least 6 months of treatment after 
relief in depressive symptoms to prevent relapse [24-26]. However, many users discontinue 
antidepressants earlier than recommended and much focus has been put on proper 
adherence and persistence [‘compliance’] to maintenance treatment [27, 28]. In chapter 2.4, 
a median persistence of 137 days was reported, thus the largest part of the antidepressant 
users did not reach the recommended duration of treatment. Female gender, SSRI and 
other antidepressant use, dependent living situation, concurrent benzodiazepine use and 
presence of depressive disorders or anxiety disorders were all associated with a longer 
duration of treatment. These factors might all relate to the presence of a psychiatric disorder 
with a more severe, chronic or relapsing character [3, 10, 29]. Also, as discussed, our wide 
range of indications for antidepressant use in the elderly population (in chapter 2.3) may 
be associated with complaints of a more chronic character. Furthermore, over the 20-year 
study period, first choice of treatment shifted from TCAs to SSRIs and other antidepressants, 
and the latter two groups were also associated with a longer duration of treatment in later 
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years or when compared to use of TCAs. We also reported a steeper increase in prevalent 
adequate antidepressant treatment (i.e. exclusion of incidental users [‘single fillers’] and at 
least 4 dispensings in a year), which might suggest that duration of treatment did indeed 
increase over the years. However, no firm conclusions can be drawn as to whether this 
increase in duration is a good or bad development. It is unknown whether antidepressant 
prescribing according to the guidelines has improved, or whether they are inappropriately 
continued. 
Benefit-risk considerations and possible unintended effects of antidepressants
Considerations regarding benefit-risk should be taken into account when we discuss possible 
inappropriate use of antidepressants. The efficacy of antidepressants has been established 
in the treatment of major depressive disorders [30], and compared to placebo, it has been 
suggested that the benefits of antidepressants may be minimal in patients with minor 
depression or mild depressive symptoms [30, 31]. Even if proven effective, the numbers 
needed to treat were estimated at 7 for SSRIs and 9 for TCAs in primary care [32]. Thus, a 
substantial group of patients does not benefit from antidepressant use. Hence, safety of 
antidepressant use should be firmly established. SSRIs were a revolution when they came 
onto the market, especially because of their safety profile [2, 33, 34]. However, SSRIs are 
not risk free as more and more adverse drug reactions (ADR) are attributed to the use of 
SSRIs [35]. 
Therefore, we studied possible unintended effects of antidepressants in a middle-
aged and elderly population. This population is at increased risk of ADRs and drug-drug 
interactions [36, 37], while they are large-scale consumers of antidepressants and other 
psychotropic drugs [38, 39]. Moreover, relatively little is known regarding drug safety, as 
elderly are underrepresented in clinical trials [40]. In the following paragraphs, we will 
further elaborate on the unintended effects that we investigated in chapter 3.  
Chapter 3.1 and 3.2 both focus on the association between antidepressant use 
and cerebral microbleeds defined on MRI. We did not observe an association between 
antidepressants with a high affinity for the serotonin transporter and presence of cerebral 
microbleeds in chapter 3.1. In contrast, we did observe an association between use 
of all antidepressants and occurrence of cerebral microbleeds in chapter 3.2. The latter 
study probably had a better design to evaluate the temporal association between use of 
antidepressants and microbleeds. However, in that study, we observed an association for the 
total group of antidepressants and not only for antidepressants with a high affinity for the 
serotonin transporter. This might suggest that another mechanism than the proposed one 
should explain an increased occurrence of microbleeds. The originally proposed mechanism 
hypothesizes that SSRIs block reuptake of serotonin by blood platelets. Thereby, platelet 
functionality may be decreased due to reduced intra-platelet serotonin concentrations, 
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and bleeding times may be prolonged [41, 42]. Potentially, residual confounding by later 
depression may explain our results, as we were able to control for depressive symptoms 
at baseline, but not during follow-up. Also, we should consider reverse causation in our 
study as incident microbleeds could have occurred at some time before antidepressant use 
during follow-up. Biologically it has been hypothesized that microbleeds may contribute 
to the progression of depression [43]. We think that large longitudinal studies are needed 
on the association between antidepressants and cerebral microbleeds with a smaller time 
interval between MRI and with a better ability to adjust for the occurrence of depression to 
confirm or refute our results.   
In chapter 3.3, we showed a beneficial association between use of SSRIs and subjective 
sleep. SSRIs seem to have sedative properties, as they were associated with a longer total 
sleep time, better sleep quality, higher sleep efficiency and more daytime dysfunction. The 
cross-sectional and longitudinal results were in line, which further supports the robustness 
of our results. However, as the results were most prominent in continuous users and not in 
incident users, this may indicate that only the sleep quality of some persons may benefit 
from SSRI use. Participants – who benefit from the SSRI – most likely continue intake. 
Therefore, with our study in a population-based setting in which we were able to account 
for depressive symptoms and benzodiazepine use, we filled an important gap in literature. 
In previous literature, subjective sleep is almost consistently better in SSRI users or improves 
during treatment, but this might represent a relief in depressive symptoms as sleep and 
depression are highly correlated [44-47]. This is confirmed by the fact that studies in non-
depressed individuals reported inconsistent results [45-53]. Ideally, further studies should 
make a direct individual comparison between subjective and objective sleep measurements 
in a population-based setting.
Chapter 3.4 concerns a study on antidepressant-induced hyponatremia, a known but 
not yet completely investigated ADR. Previous literature on SSRI-induced hyponatremia, 
consisting of case-reports, incidence studies and observational studies, has consistently 
shown an association [35, 54-59]. However, studies on its association with TCAs and other 
antidepressants are scarce and results are inconsistent [35, 58, 60-63]. The hypothesized 
mechanism – syndrome of inappropriate antidiuretic hormone secretion (SIADH) – could 
also apply to certain serotonin specific TCAs and other antidepressants [55, 62, 64, 65]. 
Nevertheless, we did not observe a statistically significant association between TCAs, other 
antidepressants and hyponatremia. Besides, confounding by indication probably influenced 
our results, as past use of TCAs and other antidepressants was also associated with a non-
significantly higher risk of hyponatremia. These drugs might be prescribed to participants 
with specific comorbidities (e.g. diabetes mellitus) which could increase the susceptibility 
to hyponatremia. This was not the case for SSRIs, they were consistently associated with 
hyponatremia in new users and during the first 30 days of use. Based on the literature 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
General discussion  |  151
4
already available on SSRI-induced hyponatremia [55, 58, 60, 66], the fact that SSRI-induced 
hyponatremia can have a reported occurrence between the 0.06% up to 40%, with a higher 
occurrence in the elderly [57, 58], and the serious consequences of even mild hyponatremia 
[67, 68], we think that – especially in a frail elderly population – sodium measurements 
could be of value for new SSRI users in the first 30 days after initiation of treatment. This 
could be added to the already existing guidelines, from the HARM-wrestling criteria [69], 
for sodium measurements in concurrent users of thiazides and SSRIs in the elderly (aged 70 
years and over) in the Netherlands. 
In chapter 3.5, we did not observe an association between use of SSRIs and bone 
mineral density (BMD), or decline in BMD. Based on a proposed biological mechanism [70, 
71], previous cross-sectional studies and (inconsistent) longitudinal studies [72-80], we 
would have expected an association between SSRIs and BMD or change in BMD. SSRIs are 
thought to play a role in bone metabolism by modulation of serotonin levels, and peripheral 
serotonin is hypothesized to decrease osteoblast proliferation [70]. However, centrally acting 
and peripheral serotonin work in opposing manners, and although most animal and cell 
studies reported a negative effect on BMD, they were not consistent [71, 81-84]. Previous 
cross-sectional studies were mostly limited by their measurement of BMD at one point in 
time and exposure assessment based on interview data [72-77]. In longitudinal studies, 
only interview data was available and duration of SSRI treatment was not always taken 
into account [78-80]. Bone remodeling is a slow process [85] and potent bone remodeling 
drugs such as denosumab take one to six months to enhance BMD [86, 87]. Therefore, it 
is questionable whether these cross-sectional studies demonstrated a real drug effect or 
represented residual confounding – most likely – by depression. Although observational 
studies are always subjected to possible bias and residual confounding, we took duration of 
use into account and were able to adjust for presence of depressive symptoms. Thus, based 
on our results, the inconsistent longitudinal studies and undefined proposed mechanism, 
we think that SSRIs are not negatively associated with BMD or that such an effect is minimal. 
Methodological considerations
Exposure assessment 
Important considerations should be taken into account when determining drug exposure. 
We used three methods to assess exposure: prescriptions from general practitioner (GP) 
medical records, pharmacy dispensing data and interview data. In observational research, 
pharmacy records are often considered as the best indicator for real drug use, since extensive 
information is available on a day-to-day basis, including duration and daily or cumulative 
dose of the dispensings. Moreover, recall bias is not an issue with prospectively gathered 
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drug exposure, and dispensings represent ‘actual intake’ better than prescriptions from 
GP or specialists because patients may decide not to fill their prescriptions at a pharmacy. 
Especially in longitudinal study designs – with interest in a potential role of cumulative 
exposure of interest – dispensing data are more informative and reliable when patients 
keep coming back for their medicines. 
Besides the studies described in chapters 2.2, 2.3 and 3.4, we used dispensing data to 
assess our exposure of interest. Analyses in chapter 2.2 and 3.4 were performed within 
the IPCI database, with prescription data from GP medical records. We used the IPCI 
database because of the large number of antidepressant users, representativeness of the 
total Dutch population, and the large number of hyponatremic events. Chapter 2.3 was 
based on interview data since our outcome of interest (indication for use) was based on 
the same interview. All other exposures of interest were determined based on dispensings 
or episodes of antidepressant use. Dispensing data from Dutch pharmacy records include 
variables such as date of dispensing, total number of tablets dispensed, total number of 
defined daily doses and the dosage regimen. With this information the duration of an 
individual dispensing can be defined and based on these individual dispensings a drug 
treatment episode can be composed. In clinical practice, consecutive dispensings are never 
collected exactly after each other. Patients collect their dispensing before or after the end 
of the previous dispening, leading to overlap or a gap between dispensings. Overlapping 
dispensings were not accounted for as we assumed that gaps compensate for the overlap 
between dispensings in people who use drugs long term or chronically. However, this is only 
an assumption and might not always account for all cases. If we would take the overlap into 
account the total duration of an episode of use would increase [88]. However, differences 
in treatment length between the two methods are smaller when a larger gap is allowed 
between the consecutive dispensings (i.e. at least 90 days) [88]. In chapter 2.1 and 2.4, 
we choose 90 days as the maximally allowed gap length between dispensings. We choose 
90 days as a cut-off as we tried to focus on episodes of depression. Short gaps might not 
represent initiation of new treatment, but might characterize problems during the current 
treatment episode [88]. In other chapters – where we focused on ADRs related to the use 
of antidepressants – we considered 7 or 30 days as maximum allowable gap length between 
the dispensings. In this case, we were not primarily interested in depressive episodes, but 
in actual current drug exposure at time of the event. Allowance of a bigger gap between 
dispensings would introduce a higher chance of misclassification of exposure at time of 
the event. Nevertheless, misclassification would be similar for all antidepressant users and 
would probably be non-differential [at random] for cases and controls. There is no golden 
standard in assessment of drug exposure and the definitions of treatment episodes in 
pharmacoepidemiological research. At start of a study, these important considerations (e.g. 
type of treatment and exposure of interest) should be taken into account when determining 
exposure based on pharmacy records. 
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Classification of antidepressant use 
As discussed before, antidepressants should not be prescribed without sound reason. ADRs 
are common with antidepressant use, especially in a population such as the elderly [37]. 
Studies in a real-life setting are needed to investigate the safety of antidepressants in a 
specific population such as the elderly. However, when studying ADRs, some considerations 
should be taken into account. 
Antidepressants are a very heterogeneous drug class. They not only have different 
applications in clinical practice [10], but also have different mechanisms of action. They 
are subdivided by the World Health Organization based on their main mechanism of 
action: TCAs, SSRIs, monoamine oxidase inhibitors (MAO’s, A or non-selective), and other 
antidepressants [89]. However, as the World Health Organization Collaborating Centre for 
Drug Statistics Methodology already points out: ‘The various antidepressants have different 
modes of action, and the classification will not reflect the exact mode of action of the 
various antidepressants’ [90]. This makes it difficult to study unintended effects for the 
different groups. Most ADRs are related to the pharmacological effect of the drug (type 
A), thus related to the mechanism of action. These ADRS are dependent on their binding 
properties for transporters and receptors, are predictable and dose dependent [91, 92]. 
Since the current classification of antidepressants does not reflect the exact mode of action, 
the question remains how we should then classify antidepressants in drug safety research. 
First, ideally, we would like to study each antidepressant as an individual agent 
(as done in clinical trials). However, because of relatively low numbers of users of most 
individual drugs and the rare occurrence of some ADRs, this is often not feasible in 
observational studies. Second, an alternative categorization has been proposed by Derijks 
et al. [93]. They already pointed out discrepancies in the traditional categorization and 
proposed a new categorization based on the pharmacological binding properties of the 
antidepressants. Clomipramine, venlafaxine, nortriptyline and maprotiline would be re-
classified into another cluster. Clomipramine and venlafaxine have a high affinity for the 
serotonin transporter, while they are originally classified as TCA or other antidepressant 
(i.e. serotonin noradrenalin reuptake inhibitor), respectively. Nortriptyline and maprotiline 
actually have a less heterogeneous binding profile than the other TCAs and have a specific 
affinity for the NE transporter, serotonin2c and histamine1 receptor [93]. Derijks et al. already 
reported that their new classification would better predict type A ADRs in clinical practice 
[94], but of course, only further studies can confirm or refute that. Third, the exposure of 
interest can be categorized based on the proposed mechanism of action of a specific ADR. 
For example, an increased risk of abnormal bleedings has been established for serotonin 
specific antidepressants (mostly SSRIs) [95-97]. SSRIs block the uptake of serotonin into 
the platelets and thereby impair platelet aggregation [41, 42, 96, 98]. This physiological 
mechanism has been studied extensively. Therefore, in chapter 3.1 and 3.2, where we 
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studied the association between antidepressants and presence and occurrence of cerebral 
microbleeds, antidepressants – the exposure of interest – were categorized based on their 
affinity for the serotonin transporter. 
However, in all other chapters regarding drug safety, we used the traditional categorization 
of antidepressants from daily practice. We used these definitions in chapters 3.3 to 3.5 for 
multiple reasons. First, the underlying mechanisms for the unintended effects mentioned 
in these chapters were still inconclusive [62, 65, 70, 71]. Second, already existing clinical 
guidelines are specific for these groups, such as the national HARM-wrestling guidelines on 
sodium assessment after concurrent use of SSRIs and thiazides in the elderly [69]. Third, our 
research questions were only relevant for a specific class of antidepressants. For example, 
SSRIs were only studied in relation to sleep quality as TCAs are often prescribed as sleep 
medication – because of their sedating effect – in clinical practice [10, 51]. Thus, we mostly 
used the classical categorization for multiple reasons. Still, it is important to emphasize the 
possible differences between the mechanisms of action within an antidepressant drug class. 
These considerations can help in decision-making to prescribe and switch from a specific 
antidepressant in daily practice. 
Bias and confounding
In all observational studies, bias and confounding may influence the study findings. The 
most common biases in epidemiological research are selection bias and information bias. 
Selection bias was minimal in our studies as all data (Rotterdam Study and IPCI database) are 
population-based [99-101]. However, in a prospective cohort study such as the Rotterdam 
Study a healthy volunteer bias may be considered as a sort of selection bias [102]. IPCI 
covers a complete population of community-dwelling people because in the Netherlands, 
every inhabitant is designated to a single general practitioner and also hospital in- and 
outpatient care is routed via the GP. Information bias is also unlikely as data were gathered 
prospectively without prior knowledge of the research questions. Antidepressant exposure 
was based on pharmacy or prescriptions records which could lead to some misclassification 
of exposure if patients do not swallow their pills. However, we assume bias is non-differential 
as misclassification will not be different for diseased and controls. Misclassification of 
outcome might have been present in our study on hyponatremia. Cases of hyponatremia 
were defined based on medical records, with a serum sodium level below 130 mmol/l, 
and/or with a hospital admission with diagnosis of hyponatremia. However, detection 
of hyponatremia might have been different for antidepressant users and non-users. GPs 
might monitor patients on SSRIs for low serum sodium levels, while hyponatremia can often 
occur unrecognized in other patients. We tried to minimize bias by performing a sensitivity 
analyses in IPCI which included only hyponatremia cases defined at hospital admission, and 
not by (GP) laboratory measurements. 
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However, in the chapters in this thesis, confounding by indication was our main issue. 
Confounding by indication occurs when an indication is an independent risk factor for the 
event among non-exposed persons, but is also associated with the exposure of interest [103]. 
Studies with use of antidepressants as exposure of interest almost always have to deal with 
confounding by indication, i.e. depression. Depression itself is associated with many of our 
outcomes of interest, i.e. cerebral microbleeds, sleep quality and BMD [43, 104-106]. It has 
been hypothesized that depression contributes to the progression of microbleeds [43]. Also, 
depression and sleep quality are highly correlated. Insomnia is a risk factor for depression, 
while depression is a risk factor for poor sleep [104, 105, 107]. Finally, depression has also 
been associated with a low BMD. A direct physiological effect has been proposed by which 
depression lowers BMD, next to a less active physical pattern and immobility [106]. For 
hyponatremia, depression is not considered a risk factor. However, other indications for 
antidepressant use could be risk factors for hyponatremia. For example, neuropathic pain 
– most commonly present in diabetes mellitus patients – is an off-label indication for use 
of antidepressants while diabetes mellitus itself is a risk factor for hyponatremia [108, 109]. 
To summarize, confounding by indication can influence our results in all chapters on drug 
safety. We tried to minimize confounding by indication in several ways: 1) All analyses within 
the Rotterdam Study were adjusted for presence of depressive symptoms. 2) We took 
different groups of antidepressants as exposure of interest. For example, we observed an 
association between all antidepressants (low to high affinity for serotonin transporter) and 
occurrence of cerebral microbleeds. This might suggest that not the affinity for serotonin, 
but another variable or mechanism might explain the results, i.e. the underlying depression. 
3) We selected past users as reference population instead of non-users. If the indication 
for treatment and accompanying specific patient characteristics will be associated with the 
outcome of interest, also past users might have an elevated risk. However, as depression is 
a transient recurrent disorder, this is a time-dependent confounding factor. Probably other 
characteristics of patients with a history of depression can also contribute to an elevated 
risk (e.g. a high number of comorbidities, polypharmacy). In chapter 3.4, we observed an 
association between past TCA users and hyponatremia. This might indicate that not the TCA, 
but the indication – in this case maybe neuropathic pain in specific patient populations – 
might explain the elevated risk of hyponatremia. 
Clinical Implications and directions for future research 
Our results provide additional insights into utilization and safety of antidepressants in the 
middle-aged and elderly population in clinical practice. Results from daily practice are very 
useful as antidepressants are not always prescribed according to the guidelines, and ADRs 
in the elderly are difficult to predict on the basis of clinical trials alone. 
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Guidelines of the Dutch General Practitioners Association (NHG) justify antidepressant 
use for major depressive disorder, anxiety disorder and as second option in the treatment 
of dysthymia [25, 110]. However, our results suggest that antidepressants are prescribed 
for a wider range of (off-label) indications. Antidepressant use for neuropathic pain, mild 
depressive symptoms, sleeping disorders and stress are off-label, and solid unbiased 
evidence of efficacy for these indications from randomized-controlled clinical trials is 
inconsistent or missing [30-32, 111, 112]. Thus, unjustified antidepressant prescribing 
seems common in the middle-aged and elderly population in daily practice. In contrast, 
a study by Piek et al. reported that most antidepressant use in primary care was justified 
in the Netherlands [113]. Only 5% had no current justification for antidepressant use. 
However, they studied antidepressant use in a population who screened positive for 
affective disorders. Prescriptions for other indications – than depression and anxiety – might 
still be unjustified. As randomized-controlled trials for registration of off-label indications 
are sparse, evidence from observational research and clinical practice should also be taken 
into account – to assess the risks and benefits for other indications – when prescribing an 
antidepressant to an individual patient [112].
Surprisingly, only 5% overtreatment was observed by Piek et al. and for a large part 
this was because of unjustified continuation of treatment. Users only had a justified reason 
for antidepressant treatment earlier in time [113]. Relatively, more chronic or long-term 
antidepressant users may explain the longer duration of treatment. However, problems with 
initiation and early discontinuation of treatment are also still a problem in daily practice 
[27, 28, 114]. For example, single dispensings were common in our population. People who 
discontinue antidepressant use after one dispensing probably changed their mind regarding 
the need for treatment or experienced ADRs. In the case of ADRs, treatment should be 
switched to another antidepressant. Moreover, after initiation of treatment, Dutch guidelines 
recommend that effectiveness is determined after 4 to 6 weeks of treatment. After good 
response (i.e. decrease in depressive symptoms), antidepressant use should continue for at 
least another 6 months of treatment. Multiple years or chronic use of antidepressants are 
only justified in patients with chronic or recurrent major depressive disorder [25]. In the 
continuation phase of treatment there is room for improvement. Our median duration of 
treatment was 137 days, and although persistence was better for psychiatric indications and 
in SSRI users, other indications for antidepressants are also often chronic and require long-
term treatment. We would suggest that more extensive information provided by the GP, 
better monitoring and check-ups can help to continue maintenance treatment [115-117]. 
Unfortunately, we can only provide some recommendations and we cannot draw any firm 
conclusions based on our results. We would need more information regarding considerations 
made by the patient and GP, and more information on patient-doctor communication. 
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Furthermore, we would like to make a recommendation for clinical practice. Based on 
our results from chapter 3.4, we would suggest that – in the elderly population – sodium 
measurements could be of value in the first 30 days of treatment and for new SSRI users. 
Although we only defined an increased relative risk for incident and short term SSRI users, 
high rates of SSRI-induced hyponatremia (between 0.06% and 40%) and conclusive previous 
literature would argue for an extension of the guidelines. For example, in line with the 
HARM-wrestling criteria for sodium measurements in concurrent users of thiazides and 
SSRIs in the elderly (aged 70 years and over) [69]. 
Directions for future research
We already addressed issues with the initiation and continuation phase of antidepressant 
use in daily practice. However, since duration of treatment seems to increase over the years 
[1, 3], inappropriate long-term use should also be studied in more detail. Discontinuation 
of treatment should be done with caution (i.e. a gradual decrease in dose) and the patient 
should be properly informed. Acute or even tapered discontinuation of treatment can cause 
mild or severe withdrawal symptoms, which can be perceived as a recurrent depressive 
episode [118-120]. Moreover, patients can be afraid to stop treatment because of the fear 
for relapse. Nevertheless, according to the guidelines chronic use is only justified in a small 
group of patients at high risk of chronic or recurrent depressive episodes [24, 25, 121], 
while also other patients seem to continue antidepressant use in clinical practice [122]. 
Besides, important disadvantages of long-term use are the costs, and the risk of ADRs and 
drug-drug interactions. Especially in an ageing population, a high number of concomitantly 
used drugs is undesirable, particularly if the daily intake includes one or more psychotropic 
drugs. Also, effectiveness of antidepressant use in the elderly population in daily practice 
should be further established. Antidepressants are not only prescribed for traditional major 
depressive and anxiety disorders. Evidence for effective treatment of antidepressants for 
these indications or for this specific population of elderly is not firmly established. More 
evidence from clinical practice might help to further improve evidence-based prescription 
of antidepressants in the Dutch elderly population. 
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Summary
Recently, it was estimated that almost 1 million persons in the Netherlands were prescribed 
an antidepressant in 2013. This is approximately 5.8% of the total Dutch population. 
Antidepressant use increased excessively since the introduction of selective serotonin 
reuptake inhibitors (SSRIs) on the market in the late 80’s. Multiple explanations for this 
steep increase have been proposed such as better detection and treatment of depression, 
widening of the indications for prescription, milder adverse drug profile for SSRIs and a 
longer duration of treatment. Nevertheless, concerns have been raised regarding these high 
levels of antidepressant use in the general population. Efficacy of antidepressants has not 
been established for all indications and antidepressants go together with multiple adverse 
drug reactions (ADRs). Especially in specific populations – such as the elderly – evidence of 
efficacy and risk for ADRs from randomized controlled clinical trials is limited and elderly 
are at increased risk of ADRs and drug-drug interactions. Therefore, within this thesis, the 
aim was to characterize antidepressant use in the last two decades in the elderly Dutch 
population. Moreover, we investigated unintended effects related to antidepressant use in 
the elderly in daily practice. 
Utilization of antidepressants 
Chapter 2 consists of four subchapters which all study different characteristics of anti-
depressant use in the general older Dutch population in clinical practice. In chapter 2.1, we 
reported that the prevalence of antidepressant use increased over a 20-year period within 
the Rotterdam Study. The steepest increase was observed for SSRIs, and we also observed 
a shift to SSRIs and other antidepressants as first choice of treatment when compared to 
tricyclic antidepressants (TCAs). In contrast, the incidence of antidepressant use decreased 
over the years. These opposing patterns were possibly explained by a longer duration of 
treatment (i.e. smaller risk at discontinuation and more adequate treatment). Results in 
chapter 2.2 from a Dutch general practitioners health care database (Integrated Primary 
Care Information project) confirm these results. Prevalent antidepressant use, especially 
SSRIs, showed a steep increase in the last 15 years. However, specifically the incidence 
of SSRIs decreased from 2000 onwards. Levels of antidepressant use were even higher 
in the elderly population when compared to the younger population. Still, an increase in 
prevalence was similar over the different age categories. In addition, trends of indications 
for treatment were determined based on International Classification of Primary Care (ICPC) 
diagnostic codes. A shift from traditional indications (i.e. depression and anxiety) to other 
indications such as neuropathic pain and sleeping disorders was observed over the years in 
incident antidepressant users. 
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Chapter 2.3 further focused on indications for antidepressant use between 1997 
and 2008. Indications for treatment were determined based on self-report and took all 
possible symptoms and disorders into account. Depression was still the main indication 
for antidepressant treatment. Anxiety, sleep problems and stress were often mentioned 
as reasons for use of SSRIs or other antidepressants, while pain was a common indication 
in TCA users. Moreover, all indications were associated with a significantly higher level 
of clinically-relevant depressive symptoms. Our results suggest that antidepressants are 
used for off-label indications, subthreshold disorders and complex situations – with a high 
comorbidity of physical problems and psychological distress – in the middle-aged and 
elderly Dutch population. To conclude, chapter 2.4 focused on adherence and persistence 
to antidepressant treatment in a daily practice setting. Numbers of early dropout or single 
filling of a dispensing was with 23% – especially in non-psychiatric indications – high in our 
study. Moreover, with a median of 137 days of treatment, persistence of treatment was 
according to the treatment guidelines (i.e. multiple months of treatment continuation after 
remission) not optimal. Especially for non-psychiatric indications during the initiation and 
continuation phase of antidepressant drug treatment the persistence can be improved 
considerably. Nevertheless, adherence to antidepressant treatment was good in our older 
Dutch population. 
Unintended effects of antidepressants
In chapter 3, unintended effects of antidepressants were studied in an elderly Dutch 
population. Chapter 3.1 and 3.2 both focused on the association between antidepressants 
and the presence or occurrence of cerebral microbleeds. We only observed an association 
between use of antidepressants and the occurrence of cerebral microbleeds in chapter 
3.2. With this longitudinal design we could better study the temporal association between 
exposure to antidepressants and cerebral microbleeds. We observed that all antidepressants 
were associated with an increased risk of incident microbleeds and this suggests that 
the association may not be due to the hypothesized mechanism which depends on the 
affinity for the serotonin transporter. Reverse causality or residual confounding by incident 
depression could explain our results. In Chapter 3.3, we studied the association between 
use of SSRIs and subjective sleep measurements. SSRI use was associated with a better 
sleep when compared to non-use after careful adjustment for depressive symptoms and 
concurrent benzodiazepine use. SSRIs seemed to have sedative properties as they were 
associated with a 0.72 hour longer sleep duration, higher sleep quality, higher sleep 
efficiency and more daytime dysfunction. Results were consistent in cross-sectional and 
longitudinal analyses, although the association was more prominent in continuous SSRI 
users. Apparently, these results suggest that in daily practice the sleep quality of some 
persons may benefit from, continued, SSRI use. In chapter 3.4 we studied a well-known but 
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not yet completely investigated ADR, namely antidepressant-induced hyponatremia. We 
only observed an association for new users of SSRIs and during the first 30 days of SSRI use 
with an increased risk of hyponatremia. This might confirm that SSRI-induced hyponatremia 
is an ADR that is transient over time. Based on the proposed mechanism – the syndrome of 
inappropriate antidiuretic hormone secretion (SIADH) – we would also expect an increased 
risk of hyponatremia in users of certain serotonin specific TCAs and other antidepressants. 
However in our study, neither use of TCAs, nor use of other antidepressants as a class was 
associated with an increased risk of hyponatremia. Thus, with our results we could only 
confirm and complement previous evidence on SSRI-induced hyponatremia. Chapter 3.5 
focused on the association between use of SSRIs and bone mineral density or change in 
bone mineral density. Strengths of our study were the longitudinal design and the fact that 
we were able to take duration of treatment into account. Herewith, we could add important 
knowledge to the available literature. We observed no association between use of SSRIs 
and, change in, bone mineral density. Thus – based on our results – we would suggest that 
SSRIs are not negatively associated with BMD or that such an effect is minimal. 
Conclusions
To summarize, within this thesis, we aimed to study characteristics and unintended effects 
of antidepressant use in clinical practice in an ageing population. The main findings from the 
studies in this thesis are further discussed and put in a broader perspective in chapter 4. Our 
results suggest that antidepressants are prescribed for a wide range of (off-label) indications 
and there is room for improvement in the initiation and maintenance phase of treatment in 
our middle-aged and elderly population in daily practice. Therefore, possible inappropriate 
antidepressant use in the elderly population in daily practice should be targeted in future 
research. Especially in a specific population such as the elderly in which a high level of 
concomitantly used psychotropic drugs is undesirable. More evidence from clinical practice 
might help to further improve evidence-based prescription of antidepressants in the Dutch 
elderly population.
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Samenvatting
Bijna één miljoen mensen gebruikten in 2013 een antidepressivum. Dat is 5,8% van de 
Nederlandse bevolking. Het gebruik van antidepressiva is eind jaren ’80 sterk gestegen 
na de introductie van selectieve serotonineheropnameremmers (SSRIs). Tot nu toe zijn 
er veel verschillende verklaringen geopperd voor deze excessieve toename in het gebruik 
van SSRIs, zoals een betere detectie en behandeling van depressie, uitbreiding van de 
indicaties en een milder bijwerkingenprofiel. Niettemin is er veel bezorgdheid over dit hoge 
percentage van antidepressivagebruikers. Het gebruik gaat vaak gepaard met bijwerkingen 
en de effectiviteit is niet bewezen voor alle indicaties waar antidepressiva in de dagelijkse 
praktijk voor worden voorgeschreven. Vooral in een specifieke populatie zoals ouderen, 
is er bij geneesmiddelengebruik een hoger risico op bijwerkingen en geneesmiddelen-
interacties. Bovendien is deze oudere populatie vaak ondervertegenwoordigd in klinische 
studies waardoor bewijs over effectiviteit en bijwerkingen niet overvloedig is. In dit 
proefschrift werd het gebruik van antidepressiva in de afgelopen 20 jaar gekarakteriseerd in 
een populatie van Nederlandse ouderen. Daarnaast werden de mogelijke bijwerkingen bij 
ouderen bestudeerd in de dagelijkse praktijk.
Gebruik van antidepressiva 
Hoofdstuk 2 bestaat uit vier verschillende subhoofdstukken waarin verschillende aspecten 
van gebruik van antidepressiva door ouderen in de dagelijkse praktijk worden beschreven. 
In hoofdstuk 2.1 zagen we dat de prevalentie van het gebruik van antidepressiva toeneemt 
in een periode van 20 jaar binnen het Erasmus Rotterdam Gezondheid Onderzoek 
(Rotterdam Studie). De sterkste toename zagen we in het gebruik van SSRIs en tevens zagen 
we dat de eerste keuze voor een geneesmiddel verschoof van tricyclische antidepressiva 
(TCA) naar SSRI. In tegenstelling daarmee vonden we dat de incidentie van het gebruik 
van antidepressiva daalde naarmate de tijd vorderde. Dit contrast zou mogelijk verklaard 
kunnen worden door een langere gebruiksperiode; mensen stoppen minder snel met 
het antidepressivum en het gebruik is adequater. De resultaten in hoofdstuk 2.2 van een 
huisartsen-database (Integrated Primary Care Information project) bevestigen de voorgaande 
uitkomsten. Prevalent antidepressivagebruik – voornamelijk SSRIs – steeg enorm over de 
afgelopen 15 jaar, maar juist de incidentie van SSRI-gebruik daalde na 2000. Het aantal 
antidepressivagebruikers was hoger in de groep ouderen vergeleken met de jongeren, maar 
de toename in prevalentie was voor beide populaties gelijk. Bovendien onderzochten we de 
indicaties voor het gebruik van antidepressiva op basis van diagnostische codes. Incidente 
gebruikers kregen hun antidepressivum steeds vaker voorgeschreven voor andere indicaties 
dan depressie, zoals neuropatische pijn en slaapproblemen, met name bij gebruik van TCAs. 
Hoofdstuk 2.3 richtte zich verder op indicaties voor antidepressivagebruik in de periode 
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van 1997 tot 2008. De indicaties voor het gebruik van antidepressiva waren gebaseerd op 
zelfrapportage en bevatten alle mogelijke symptomen en stoornissen. Depressie was de 
belangrijkste indicatie voor antidepressivagebruik. Gebruikers van SSRIs en overige (nieuwe) 
antidepressiva noemden angst, slaapproblemen en stress vaak als reden voor gebruik, 
terwijl TCA-gebruikers vaak pijn rapporteerden. Alle indicaties waren geassocieerd met 
een significant frequentere aanwezigheid van klinisch-relevante depressieve symptomen 
vergeleken met niet-gebruikers. De resultaten suggereren dat antidepressiva worden 
voorgeschreven voor off-label indicaties, losse kernsymptomen die niet voldoen aan de 
DSM-criteria voor depressie, complexe situaties – met een hoge comorbiditeit van fysieke 
en psychologische problemen – in onze populatie van middelbare en hogere leeftijd. In 
het laatste subhoofdstuk, hoofdstuk 2.4, werden de therapietrouw en persistentie van 
antidepressivagebruik in de dagelijkse praktijk bestudeerd. Het percentage mensen dat 
meteen stopt of nooit begon, en dus maar een enkel recept ophaalde, was met 23% erg 
hoog. Dit waren voornamelijk gebruikers van antidepressiva zonder een psychiatrische 
indicatie. De persistentie van antidepressivagebruik was met een mediaan van 137 dagen 
gebruik niet optimaal volgens de richtlijnen, die adviseren om de behandeling bij een goede 
respons bij voorkeur 6 maanden voort te zetten. Vooral voor niet-psychiatrische indicaties 
kunnen de initiatie en persistentie van antidepressivagebruik verbeterd worden. Daarmee 
vergeleken was de therapietrouw, met 90%, erg goed in onze oudere populatie. 
Bijwerkingen van antidepressiva
In hoofdstuk 3 worden meerdere bijwerkingen besproken van antidepressiva bij gebruik 
in een oudere populatie. In hoofdstukken 3.1 en 3.2 zijn de resultaten van de associatie 
tussen antidepressivagebruik en de aanwezigheid of het ontstaan van cerebrale 
microbloedingen vastgelegd. Alleen in hoofdstuk 3.2 toonden we een associatie aan tussen 
antidepressivagebruik en het ontstaan van cerebrale microbloedingen. Vergeleken met 
de cross-sectionele opzet van hoofdstuk 3.1 was de longitudinale opzet van deze studie 
beter geschikt om de tijdsrelatie tussen het gebruik van antidepressiva en cerebrale 
microbloedingen te bepalen. De resultaten toonden aan dat alle antidepressiva het risico 
op cerebrale microbloedingen verhoogden. Dit zou betekenen dat het mechanisme dat 
ten grondslag ligt aan het verhoogde risico waarschijnlijk niet samenhangt met de affiniteit 
voor de serotonine-transporter maar er sprake lijkt te zijn van een onbekend mechanisme, 
tenzij omgekeerde causaliteit of verstorende factoren de resultaten verklaren. In hoofdstuk 
3.3 hebben we gekeken naar de associatie tussen het gebruik van SSRIs en slaapkwaliteit. 
Het gebruik van SSRIs was geassocieerd met een betere slaapkwaliteit, nadat factoren als 
depressieve symptomen en gelijktijdig benzodiazepine gebruik meegenomen werden in de 
analyses. Het lijkt erop dat SSRIs een sederende werking hadden: ze waren geassocieerd met 
een langere slaaptijd, een hogere slaapkwaliteit, hogere slaapefficiëntie en meer verstoring 
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van het ritme overdag. De resultaten waren in de cross-sectionele en longitudinale analyses 
consistent en de effecten waren vooral aanwezig in de groep continue SSRI-gebruikers. De 
resultaten tonen aan dat in de dagelijkse praktijk sommige mensen profijt kunnen hebben 
van continu SSRI-gebruik voor een betere slaapkwaliteit. In hoofdstuk 3.4 hebben we 
een bekende bijwerking van antidepressiva bestudeerd, namelijk hyponatriemie tijdens 
gebruik van SSRIs. Wij zagen alleen een associatie tussen het gebruik van antidepressiva 
en hyponatriemie voor nieuwe SSRI-gebruikers en tijdens de eerste 30 dagen van SSRI-
gebruik. Dit suggereert dat hyponatriemie geassocieerd met SSRI-gebruik een bijwerking 
is die van voorbijgaande aard is. Gebaseerd op het voorgestelde mechanisme – syndroom 
van inadequate secretie van antidiuretisch hormoon – zouden we ook een verhoogd risico 
op hyponatriemie verwachten voor bepaalde TCAs en overige antidepressiva die ook 
serotonine-specifiek zijn. Dit kwam in onze studie niet naar voren; met onze studieresultaten 
hebben we aldus voorgaande studies over door SSRI-veroorzaakte hyponatriemie bevestigd 
en aangevuld. Hoofdstuk 3.5 beschrijft een onderzoek naar het gebruik van SSRIs en de 
associatie met botdichtheid en een verandering in botdichtheid. In cross-sectionele studies 
zijn SSRIs consequent geassocieerd met een lagere botdichtheid, terwijl longitudinale studies 
inconsistente resultaten laten zien. De belangrijkste toegevoegde waarden van onze studie 
ten opzichte van eerdere publicaties waren de longitudinale studie-opzet en het feit dat we 
daarbij gegevens hadden over de duur van antidepressivagebruik. We vonden geen enkele 
associatie tussen SSRI-gebruik en botdichtheid of een afname in botdichtheid. Gebaseerd 
op onze resultaten kunnen we concluderen dat SSRIs niet negatief geassocieerd zijn met 
botdichtheid, al kunnen we niet uitsluiten dat er sprake is van een zeer gering effect. 
Samenvattend: in dit proefschrift hebben we geprobeerd om karakteristieken en 
bijwerkingen van antidepressivagebruik in de dagelijkse praktijk in een oudere populatie 
te bestuderen. De belangrijkste bevindingen van de studies in het proefschrift worden 
verder besproken in hoofdstuk 4. Onze resultaten tonen aan dat antidepressiva worden 
gebruikt voor uiteenlopende indicaties die geregistreerd, beschreven in behandelrichtlijnen 
of mogelijk off-label zijn. Bovendien is er ruimte voor verbetering bij de initiatie en 
onderhoudsbehandeling met antidepressiva in onze populatie van middelbare en hogere 
leeftijd. Meer resultaten van onderzoek uit de dagelijkse praktijk zou het evidence-based 
voorschrijven van antidepressiva in de Nederlandse oudere populatie verder kunnen 
verbeteren en mogelijk ongewenst gebruik van psychotrope geneesmiddelen kunnen 
verminderen. 
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heb mogen baseren op gegevens uit de IPCI-database. Ann, Mees, Kris en Marcel bedankt 
voor jullie hulp, variërend van opbouw van de studie, tot technische problemen en het 
openen van de deur.
Natuurlijk wil ik ook een paar namen noemen van collega’s die belangrijk zijn geweest 
tijdens mijn tijd in Rotterdam. Rikje, Daan, Eline en Toke bedankt voor het warme welkom 
toen ik net naar Rotterdam verhuisde en met dit promotietraject startte. Meisjeskamer, 
oeps, toen zaten we opeens met alle meiden op een kamer…Bedankt voor alle discussies, 
hulp bij ‘woorden uit een te lang abstract’ halen, methodologische vragen, maar vooral 
voor de leuke, gezellige en hilarische momenten! Annemarie, Lisette, Henriette, Mariana 
en Rachel, bedankt voor alle gezellige lunches en avonden. Wanneer gaan we weer 
spelletjes spelen? Gelukkig waren de koffiepauzes ook nooit saai, in het bijzonder bedankt 
voor de gezelligheid: Gwen, Marjolein, Inge, Nico, Edith en Marten. Edith, hopelijk wonen 
of werken we in de toekomst weer bij elkaar in de buurt. Naast al deze gezelligheid werd 
er natuurlijk ook hard gewerkt. Nico, Saloua, Eline, Lisette, Annelies, Marten en Raymond 
bedankt voor de fijne samenwerking. Juist de projecten waarin er werd samengewerkt met 
promovendi met verschillende achtergronden waren erg leerzaam. Raymond, wij hebben 
ons promotietraject samen afgelegd. Bedankt voor alle input, hulp, brainstorm sessies en 
discussies. Veel succes met je verdere wetenschappelijke carrière. 
Inmiddels ben ik sinds augustus zes verdiepingen lager aan het werk bij de afdeling Medische 
Ethiek en Filosofie van de Geneeskunde aan het Erasmuc MC. Bedankt voor het warme 
welkom! In het bijzonder door Suzanne en Eline. Ik hoop dat het vervolg van het project net 
zo spannend, interessant en leerzaam is. 
Lieve beachvolleybal-chicks en -dudes, wat zou ik toch zonder jullie moeten? De zomers 
zijn altijd geweldig, of het nou op Ameland, Vrouwenpolder, Bakkum, Scheveningen of 
Frankrijk is, met jullie is het altijd fanatiek sporten, maar vooral heel gezellig! Bedankt 
trainingsmaatjes, teamgenootjes, mede-kampeerders en mede-Corona drinkers. In het 
bijzonder wil ik mijn twee teamies bedanken. Lot, wij hadden drie jaar lang Aarts/Heida bij 
ons op nummer 1 staan op de prioriteitenlijst in de zomer: veel trainen, toernooien spelen, 
hard werken, maar vooral veel lachen. Ook al is die tijd voorbij, ik ben blij dat we elkaar nog 
geregeld zien en goede vriendinnen zijn. Ik kan niet wachten tot ik met James mag mixen. 
Maureen, Mauttie, wat deden wij het soms boven verwachting goed hè? Oeps…1e divisie 
gewonnen, 13e bij het Nederlands Kampioenschap. ‘It’s on when it’s on!’ Bedankt voor de 
slappe lach, slechte grappen en relativering op de spannende momenten. Laten we onze 
avonden stappen, wijntjes drinken, eten en Wii-spelen er inhouden. 
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Lieve Quirine en Jesse, ook al hebben we elkaar niet altijd evenveel gezien tijdens mijn 
periode in Rotterdam, gelukkig waren de momenten dat we elkaar zagen vertrouwd en 
gezellig als vanouds. Wat fijn dat ik nu weer in de buurt woon. Quirine, bedankt dat jij een 
schilderij wilde maken voor de voorkant van mijn proefschrift. Ik kan me geen persoonlijkere 
en geschiktere voorkant van dit proefschrift bedenken. 
Gekke maffe lekkere jaarclub Taifoen, wat zijn we toch een lekker zooitje bij elkaar 
hè? Maar wel een zooitje van vriendinnen met veel leuke avonden, goede gesprekken, 
legendarische weekenden en vakanties. Van een date met Taifoen word ik altijd vrolijk, 
actief en daarna lijkt verder iedereen opeens zo saai…Op naar onze volgende hilarische en 
memorabele vakantie!
Alle vrienden en vriendinnen uit Wageningen, bedankt voor de leuke en soms nostalgische 
dates. Fari, roomie, wat gezellig dat we nu weer samenwonen. Annika, druk vriendinnetje 
ver weg, maar toch altijd betrokken en de grootste lieverd die ik ken. Rianne, wat fijn om jou 
nog steeds als vriendin te hebben, ik hoop dat dat zo blijft. Annelies en Josje, mijn mede-
promotiekandidaten en vriendinnen in Rotterdam. Ik denk dat dit promotietraject veel 
moeilijker was geweest zonder jullie. Bedankt voor ALLES! Teveel om op te noemen, maar 
onder andere jullie luisterende oor, adviezen en vooral alle gezelligheid (koffie, etentjes, 
spelletjes en sporten). En je bent nog niet van me af hoor Jos, ik achtervolg je gewoon naar 
Amsterdam. 
Lieve familie, ik besef me soms niet altijd even goed hoe waardevol het is om zo’n hechte 
familie op de Postjeskade te hebben. Joke en Wim, bedankt voor jullie interesse in alles wat 
ik doe. Neefje en nichtje, stiekem heb ik toch een grote broer en zus waar ik tegenop kan 
kijken en leuke dingen mee kan doen. Daantje en Bram, door jullie mag ik nu weer twister 
spelen, buiten voetballen, in klimrekken klimmen, Sinterklaas vieren en kinderboeken lezen. 
En dan zijn er natuurlijk nog de dikke knuffels, jullie zijn lieverds!
Lieve paps en mams, ik kan niet alles beschrijven waarvoor ik jullie wil bedanken. Jullie 
zijn er altijd voor me, steunen me bij alles en hebben dit altijd gedaan. Bedankt voor alle 
vrijheid en mogelijkheden die jullie me hebben gegeven. Mams, je onvoorwaardelijke liefde 
en zorgzaamheid zijn ongekend. Paps, kritisch doch rechtvaardig, workaholic, maar altijd tijd 
voor en trots op zijn dochter. Heb je al tranen in je ogen? 
Roel, Roelie, ‘rots in de branding’, en mijn allerliefste maatje de afgelopen jaren. Ik denk 
niet dat ik ooit nog zo’n leuk iemand in de bus zal ontmoeten. Bedankt voor alle liefde, 
begrip, steun, vertrouwen en mooie momenten in de afgelopen jaren. Ook al zat je ver weg 
in Maastricht, je was altijd betrokken en toch dichtbij. Ik wil nog zoveel nieuwe avonturen 
met jou beleven. 
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Curriculum Vitae
Nikkie Aarts werd op 16 januari 1987 geboren te Amsterdam. Het VWO-diploma behaalde 
zij aan het Montessori Lyceum Amsterdam. In 2005 startte zij met de Bachelor Voeding 
en Gezondheid aan de Wageningen Universiteit. De Master Voeding en Gezondheid, met 
de specialisatie Epidemiologie en Public Health behaalde zij tevens aan de Wageningen 
Universiteit. Als onderdeel van deze Master heeft zij 6 maanden onderzoek gedaan naar 
de effecten van eiwitsuppletie bij patiënten met taaislijmziekte in Little Rock, Arkansas, 
Verenigde Staten.
In 2011 verhuisde ze naar Rotterdam om daar te beginnen aan haar promotietraject 
aan het Erasmus MC bij de afdelingen Inwendige Geneeskunde en Epidemiologie. Dit 
promotieonderzoek stond onder leiding van prof.dr. Bruno H.Ch. Stricker en dr. Loes E. 
Visser in het kader van het ZonMw programma ‘Priority Medicines Elderly’. Het doel was 
om verschillende aspecten van antidepressivagebruik door ouderen in de dagelijkse praktijk 
te bestuderen. Nikkie richtte zich onder andere op karakteristieken van het gebruik en de 
bijwerkingen van antidepressiva, waarvan de resultaten zijn beschreven in dit proefschrift. 
Op dit moment woont Nikkie weer in Amsterdam en werkt ze als onderzoeker op de 
afdeling Medische Ethiek en Filosofie van de Geneeskunde aan het Erasmus MC, waar zij 
ethische en maatschappelijke problemen in kaart brengt rondom de wereldwijde ambities 
van het bedrijf myTomorrows binnen het NWO-project: ‘Nice to meet? Meeting unmet 
medical needs: a social innovation to facilitate early access to investigational drugs’. 

